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1. INTRODUCTION 
1.1. Psoriasis, a complex inflammatory skin disease 
Psoriasis is a multifactorial skin disorder affecting about 2-3% of the population world-
wide, although it is more prevalent in European, American and Canadian populations (1). The 
most common form of chronic plaque psoriasis is Psoriasis vulgaris, which is characterized by 
epidermal hyperplasia, intensified and abnormal dermal angiogenesis and infiltration of 
inflammatory cells (Figure 1). Altered cellular composition characterized by hyperproliferation 
of keratinocytes and massive infiltration of immune cells is initiated by secreted cytokines of 
activated resident immune cells, dendritic cells, macrophages and innate immune cells as well 
as by keratinocytes themselves in the psoriatic skin (2, 3).  
Both genetic risk factors and environmental triggers are known to contribute to the 
pathomechanism of psoriasis. Psoriasis-susceptibility (PSORS) loci are areas of chromosomes 
thought to associate with the manifestation or maintenance of psoriasis. At least 15 different 
PSORS have been identified by linkage analysis in family-based studies, for example PSORS1 
is the strongest susceptibility locus known as HLA-C (4, 5). In recent years, genome-wide 
association studies (GWAS) have identified single nucleotide polymorphisms (SNPs) in 50 
different regions of the human genome that are connected with psoriasis. The function of these 
polymorphic genes is comprehensive, such as antigen presentation (HLA-Cw6), T cell 
development and polarization (STAT3), innate immunity (CARD14) and negative regulators 
of immune responses (SOCS1) (1).      
One of the environmental factors involved in psoriasis is the streptococcal infection of 
the tonsils, where even after the infection is cleared, T cells remain auto-reactive to keratin 
peptides (6, 7). Acute stressful emotional events like accidents, examinations, sexual assaults 
or death of relatives have also been related to the onset of the disease. Moreover, a correlation 
between high stressed group and psoriasis area and severity index (PASI) score has also been 
established (8, 9). Physical trauma including cuts, scarring, sunburn and Koebner response may 
also lead to the induction of psoriasis (10, 11). Lifestyle could play a role in modifying psoriasis 
pathogenesis. Among these factors diet (polyunsaturated fatty acids, gluten and alcohol), 
smoking and ultraviolet radiation are suspected (12-15).  
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Several studies focused mainly on the lesional skin and as a result of these efforts now 
it is well characterized that psoriasis is a chronic, inflammatory skin disease in which both 
innate and adaptive immune activation play a role in the manifestation and the maintenance of 
the abnormal skin phenotype (16). However, much less is known about the contribution of 
resident cells of the tissue to the pathology of the disease. Therefore, we focused on to seek for 
alterations in tissue responses in psoriasis by investigating the phenotypically normal looking 
non-lesional (NL) psoriatic skin.  
 
 
Figure 1. Non-lesional (NL) and lesional (L) psoriatic skin. Psoriatic lesional skin manifests as raised, red scaly 
and well- demarcated plaques. Non-lesional skin is marked with red. The picture is from the clinical archive of the 
Department of Dermatology and Allergology, University of Szeged. 
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1.2. Structure and function of fibronectin 
1.2.1. The role of fibronectin-binding integrins 
Integrins are cell-surface heterodimeric transmembrane receptors consisting of an α and 
a β subunit. Integrins are known to play essential roles in connecting the intracellular 
cytoskeleton with various components of the extracellular matrix (ECM). Through these 
interactions integrins transduce mechanical and chemical information from the extracellular 
space into the intracellular environment and regulate specific signal transduction cascades. 
Fibronectin (FN) is a protein secreted as a soluble dimer and through interactions with integrins 
they form fibrillar structures. The main FN receptor α5β1 integrin was found to be overexpressed 
in the NL psoriatic epidermis relative to normal (17, 18). There is evidence that the proper 
regulation of integrin expression in keratinocytes is essential for normal epidermal homeostasis 
as shown by the suprabasal overexpression of integrins in transgenic mice resulting in epidermal 
hyperproliferation and inflammatory reaction (19). 
In the steady state of normal human adult epidermis α5 integrin expression of 
keratinocytes is downregulated. A possible explanation of α5 integrin overexpression in NL skin 
is the presence of FN and one of its isoforms, the extra-domain-A containing fibronectin 
(EDA+FN) in the microenvironment of basal keratinocytes (18, 20). The EDA+ domain contains 
an additional non-classical (non-RGD) binding site (EDGIHEL) for α4β1, α9β1 and α4β7 integrins 
(Figure 2) (21). α4β1 integrin conveys the EDA-induced stress fibers, myosin light chain 
phosphorylation, fibrillogenesis, fibronectin synthesis and deposition (22). 
10		
 
Figure 2. Schematic domain structure of fibronectin and positions of binding sites of interaction partners. 
The different types of homologous domains (12 Type I, two Type II and 15 Type III) are represented. Conservative 
(RGD) and alternatively spliced (LDV), synergy (PHSRN) and EDA (EDGIHEL) binding sites are indicated, 
together with their integrin receptor partners. EDA and EDB splicing is similar in all species, while that of the 
IIICS region is species-specific (five variants in humans, three in rodents and two in chickens) (21). (Modified 
figure based on the publication of White et al., 2008.) 
1.2.2. Structure and function of EDA+FN and FN  
FN is a multifunctional component of the ECM. FN filaments interact with other ECM 
components including fibrin, fibulin-1, heparin, syndecans, cartilage oligomeric matrix protein 
(COMP) (23) and collagens (24). Matrix FN provide a base to the cells and regulate the cellular 
behavior through the transfer of biochemical and mechanical signals. There are two major 
distinct forms of FN: the plasma and the cellular FN. The secondary structure of FN consist of 
the following domains: type I, II and III repeats (Figure 2). Type I and II domains are stabilized 
by disulphide bonds in contrast to the type III domains that consist of seven anti-parallel beta-
strand which are arranged into two distinct beta-sheets (25, 26). FN could contain one or two 
extra Type III domains, named Extra Domain A and B (EDA and EDB, respectively). These 
two domains could be inserted/excluded through alternative splicing (21). The alternatively 
spliced ED sequences are lacking from the plasma FN secreted mostly by hepatocytes. In 
contrast, the cellular form of FN contains the EDA domain and found incorporated into the 
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ECM of tissues. Several stromal cell types are able to produce cellular fibronectin but the main 
source of this protein are the fibroblasts. The alternative splicing of FN is regulated by splicing 
regulator (SR) proteins. The regulatory sequence of EDA is a purin-rich region found within 
the exon itself (27) and is recognized by splicing factor 2 (SF2) /alternative splicing factor 
(ASF) (28). 
The production of alternatively spliced forms is the highest during embryonic 
development. Postnatal the amount of the protein is reduced and further decreases with ageing 
(21). However, elevated amount of the EDA+FN is observed during tissue repair, wound 
healing, angiogenesis and in highly proliferating adult tissues, it can influence cell adhesion, 
differentiation, cell cycle progression (29-31). The EDA+FN is appearing at the basement 
membrane of NL epidermis compared to normal skin (20, 32). TGFβ1 is known to enhance 
EDA+FN production in wounded tissues (33). Moreover, EDA+FN can modulate matrix 
remodelling by the regulation of cytokine-dependent matrix metalloproteinases (34). EDA+FN 
can activate matrix metalloproteinase 9 (MMP9) and NF-κB production via Toll-like receptor 
4 (TLR4) thereby contributing to the manifestation of inflammatory responses (30). In human 
dermal fibroblasts EDA+FN was described to stimulate the expression of pro-inflammatory 
cytokines including CXCL1-3 (35) and to induce interleukin 8 (IL-8) expression through NF-
κB and p38/MK-2 signaling cascade (36). 
1.3. The role of KGF in health and disease 
1.3.1. Structure and function of KGF 
Fibroblast growth factors (FGFs) are small growth factor polypeptides (37) . The family 
of FGF consists of 23 members with a common structural characteristic, although there are only 
18 FGFs that are known to serve as a ligand for the four different FGF receptors (38). Most 
FGFs have an autocrine and/or paracrine function. Fibroblast growth factor 7 (FGF7), also 
known as keratinocyte growth factor (KGF) is produced by cells of mesenchymal origin and 
considered to be a major growth factor for keratinocytes. KGF was first isolated by Rubin and 
colleagues and characterized as a fibroblast produced growth factor of keratinocytes (39). In 
the skin KGF is produced by dermal fibroblasts and keratinocytes can influence its production 
through interleukin 1 (IL-1).  
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KGF is known to induce keratinocyte proliferation and differentiation. Several reports 
suggest that KGF reduces the ability of keratinocytes to initiate terminal differentiation and 
undergo programmed cell death. Overexpression of KGF in the basal epidermal cell layer of 
transgenic mice results in epidermal hyperplasia (40). There is also evidence suggesting that 
fibroblasts from L and NL skin of psoriatic patients induce keratinocyte outgrowth by producing 
soluble signals (41). More recently, it has been reported that KGF can induce the expression of 
α5 integrin and delays the expression of keratin 10 and transglutaminase in keratinocytes (42). 
Indirect evidence, such as measurement of mitogenic activity, suggests that the specific receptor 
for KGF on epithelial cells is the IIIb splice variant of fibroblast growth factor receptor 2 
(FGFR2) (43).  
1.3.2. Structure and isoforms of FGFR2 
The FGFR family consist of FGFR1, FGFR2, FGFR3 and FGFR4 encoding for 
receptors of FGFs. FGFRs are transmembrane-type receptors, composed of an extracellular 
ligand-binding domain, a single transmembrane domain and a cytoplasmic domain. The 
cytoplasmic domain of FGFRs contains the catalytic protein tyrosine kinase core and regulatory 
sequences (44). FGFRs are formed in two different ways: by the expression of different splice 
variants of the same FGFR gene that can form homo- or heterodimers or by the expression of 
two different FGFR genes that go under hetero-dimerization following ligand binding (39). 
Alternative splicing in the third immunoglobulin (Ig)-like domain provides increased ligand 
specificity for different members of the FGFR family (38, 45, 46). The extracellular ligand 
binding domain of FGFRs consists of either two or three Ig-like domains. Alternative RNA 
splicing is realized by utilizing one of the two unique Ig-like exons in designated as IIIb and 
IIIc versions in FGFR1, 2 and 3, with the exception of FGFR4 where no alternative splicing 
take place (43). FGFR2 has two isoforms FGFR2-IIIb and FGFR2-IIIc. The expression of the 
different isoforms of FGFR2 is regulated in tissue-specific manner, where isoform IIIb is mainly 
produced by epithelial cells and the isoform IIIc by mesenchymal cells (47). KGF is known to 
initiate mitogenic activity most effectively by binding to the FGFR2-IIIb splice variant. KGF 
can also facilitate cell proliferation through FGFR2-IIIc or FGFR1, but with a much lower 
efficiency (37). The schematic structure of FGF-FGFR and the formation of the two different 
FGFR isoforms by splicing are shown in Figure 3. 
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Figure 3. FGF-FGFR structure and FGFR splicing. a The basic structure of the FGF–FGFR complex comprises 
two receptor molecules, two FGFs and one heparan sulphate proteoglycan (HSPG) chain. FGFs bind with low 
affinity to cell surface HSPGs (purple) and with high affinity to specific FGFRs. The FGFRs consist of three 
extracellular immunoglobulin (Ig) domains, a single transmembrane helix and an intracellular split tyrosine kinase 
(TK) domain. The second and third Ig domains form the ligand-binding pocket and have distinct domains that bind 
both FGFs and HSPGs. b Ligand-binding specificity is generated by alternative splicing of the Ig III domain. The 
first half of Ig III is encoded by an invariant exon (IIIa), which is spliced to either exon IIIb or IIIc, both of which 
are spliced to the exon that encodes the transmembrane (48) region. Epithelial tissues predominantly express the 
IIIb isoform and mesenchymal tissues express IIIc. FGFR4 is the only member of the FGFR family that is 
expressed as a single isoform (38). (Modified figure based on the publication of Turner et al., 2010.) 
1.3.3. FGF and FGFR signaling network 
FGFs transmit their signal through binding to specific FGFRs. FGFs are secreted 
glycoproteins that are localized to the extracellular matrix and to the cell surface by heparin 
sulphate proteoglycans (HPSGs) (49). FGFs are released from the extracellular matrix by 
heparinases, proteases or specific FGF binding proteins and are associated with HPSGs on the 
cell surface, where they induce the dimerization and autophosphorylation of FGFRs (44). The 
specificity of FGF-FGFR interaction depends on the alternative splicing of FGFR. FGFs create 
a ternary complex with respective FGFRs and HPSGs (Figure 4). Following ligand binding 
FGFR monomers undergo dimerization forming homo- or heterodimers (39). Dimerization 
leads to conformational change in the receptor triggering the autophosphorylation of the 
intracellular tail. Phosphorylated tyrosine residues are binding sites to the signal transduction 
proteins, resulting in the induction or modulation of the four distinct signalling cascades: 
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phospholipase Cγ (PLCγ), mitogen activated protein kinase (RAS-RAF-MAPK), 
phosphoinositide-3 kinase (PI3K)- v-akt murine thymoma viral oncogene homolog (AKT) and 
signal transducer and activator of transcription (STAT) (38, 50) . 
Activated FGFR2 phosphorylates the FGFR substrate 2 (FRS2) to recruit the son of 
sevenless and growth factor receptor-bound protein 2 (GRB2) leading to the activation of the 
RAS-RAF-MEK-MAPK/ERK pathway. AKT-dependent anti-apoptotic signalling cascade is 
activated by GRB2-associated binding protein 1- PI3K (GAB1-PI3K) in a separate complex. 
On the other hand, the Src homology 2 (SH2) domain of PLCγ binds and activate the protein 
kinase C (PKC), which reinforces the activation of MAPK. Finally, the activation of the STAT 
pathway depends on cellular context (Figure 4). 
 
Figure 4. FGF-FGFR signalling network. Following ligand binding and receptor dimerization, the kinase 
domains transphosphorylate each other, leading to the docking of adaptor proteins and the activation of four key 
downstream pathways: RAS-RAF-MAPK, PI3K-AKT, signal transducer and activator of transcription (STAT) 
and phospholipase Cγ (PLCγ) (green) (38). (Modified figure based on the publication of Turner et al., 2010.) 
 
Nucleus 
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1.3.4. Autocrine and paracrine signaling roles of KGF and FGFR2 in pathophysiology 
and therapy 
There are several pieces of evidence highlighting the important function of KGF in the 
processes of wound healing, tissue regeneration and repair. KGF released by stromal cells 
enrols the appropiate receptor of target epithelial cells thus form paracrine stimuli facilitating 
epithelial regeneration. The paracrine signaling functions of KGF are explored for their 
therapeutic potential in mucositis and wound healing (51). Recombinant produced human KGF, 
Palifermin is already in use to treat mucositis after chemotherapy and radiotherapy (52). 
Furthermore, KGF can modify the extent of ureteric bud growth during development and the 
number of nephrons in the kidney (53) and accelerate the repair of renal tubules after chemically 
induced proximal tubule damage (54).  
Genetic alterations of FGFR2 that cause dysregulation of FGFR2 signaling can lead to 
the development of congenital disorders and acquired diseases including melanoma, Apert 
syndrome and atopic dermatitis among others (55). FGFR2-IIIb knockout mice die after birth 
due to multiple organ abnormalities including dysgenesis of the skin and agenesis of the lungs 
and limbs (56). Amino-acid substitutions around the third immunoglobulin-like domain of 
FGFR2 lead to the alteration of ligand selectivity among different FGFs (57), whereas mutations 
within the tyrosine kinase domain cause autoactivation of the receptor independently from 
ligand binding (58, 59). The FGFR2 gene is mutated in Apert syndrome, where ligand 
specificity experiments showed that the mesenchymally expressed FGF7 is able to bind thereby 
to activate the mesenchymal splice form of FGFR2 (FGFR2-IIIc) (57). Furthermore, genetic 
alterations in FGFR2 give rise to skin manifestations like melanoma, squamous cell carcinoma 
and basal cell carcinoma (59).  
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1.4. The JAK-STAT signaling pathway 
1.4.1. The role of the JAK-STAT signaling pathway in inflammation and immunity 
The Janus kinase (JAK)-STAT pathway plays an important role in both innate and 
adaptive immunity and contributes to the manifestation of several inflammatory processes. In 
mammals the JAK family consists of four tyrosine kinases: JAK1, JAK2, JAK3 and TYK2, 
while the STAT family has seven members: STAT1, STAT2, STAT3, STAT4, STAT5a, 
STAT5b and STAT6. STAT proteins share a similar structural composition: N-terminal 
domain, coiled-coil domain, DNA binding domain, linking domain, SH2 domain and 
transcriptional activation domain. 
JAK-STAT is activated by over 50 cytokines and growth factors, these cytokines include 
interferons, colony stimulating factors, several interleukins and hormones (60, 61). 
Extracellular cytokines or growth factors associate with their corresponding cell surface type I 
and type II cytokine receptors, ligand binding leads to conformational change and dimerization 
of the receptor allowing the binding of JAK pairs in the cytoplasm (62). Dimerized JAKs 
autophosphorilate and become activated enabling STAT binding and phosphorylation. 
Phosphorylated STAT monomers form dimers that are translocated into the nucleus of the cell 
and influence transcription of several genes (Figure 5) (63). 
The IFNγ-induced route of STAT1 has been well characterized. The regulation of 
STAT1 signaling by IFNγ takes place via the modulation JAK1 and JAK2 phosphorilation. 
Furthermore IFNγ activates transcription factors called interferon regulatory factors (IRF) IRF1 
and IRF8 via STAT1 (64). IRFs such as IRF1, IRF3, IRF5, IRF7 and IRF8 contribute to the 
TLR mediated signaling through the critical mediator STAT1 (65, 66). In a TLR4- dependent 
manner STAT1 phosphorylation can increase the expression of inflammatory mediators such 
as chemokine C-X-C motif chemokine 10 (CXCL10) and the adhesion molecule ICAM1 by 
IFNγ and LPS cross-talk (66). Moreover, IRF8 in association with IFNγ and LPS mediate the 
transcriptional activation of chemokine RANTES (CCL5) (67) leading to attraction of 
leukocytes to the site of injury of tissues including that of arteries. IFNγ and LPS co-
administration triggers macrophage STAT1 pool super-activation and IRF8 expression (68, 69). 
The newly synthetized IRF8 enhances the crosstalk between IFNγ and TLR inducing further 
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activation of STAT1 as well as inflammatory molecules and thereby contributing to 
antimicrobial defense (64). 
 
Figure 5. The schematic illustration of JAK-STAT signaling.  (JAK: Janus kinase; STAT: signal transducer 
and activator of transcription; P: phosphorylation) 
1.4.2. Disruption of STAT1 signaling in human diseases 
Several studies revealed alterations in the JAK-STAT signaling in chronic skin diseases 
including psoriasis, atopic dermatitis and melanoma. STAT1 was observed to be localized 
predominantly in the horny layer in normal skin by immunostaining (70). Impaired 
phosphorylation of STAT1 and STAT5 was described to cause defective response to IL-2 in 
melanoma from stage III to IV (71). STAT1 in tumors functions as a suppressor probably by 
mediating the TNFα triggered apoptotic program (72).  
Both loss-of-function and gain-of-function mutations were found in genes coding 
STAT transcription factors. Strikingly, all of the known STAT1 mutations are coupled with a 
particular type of pathogen. Patients with STAT1 loss-of-function mutations are more prone 
to mycobacterial and viral infections, whereas gain-of-function mutations increase 
susceptibility to fungal infections (73, 74). 
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2. AIMS 
The pathogenesis of psoriasis is still not fully understood, numerous studies have proposed 
hypotheses regarding to immune dysregulations (3), skin microbiota system (75) or 
extracellular matrix alterations (76) among others to play essential roles in the development of 
the disease. A continuously growing body of evidence indicate that the healthy looking NL 
psoriatic skin represents an unbalanced phenotype and carries structural alterations compared 
to normal skin making it susceptible for developing the disease. Abnormalities of the basement 
membrane at the dermal-epidermal junction (DEJ) render the uninvolved skin to become 
activated and present a chronic wound healing phenotype.  
FN is capable to enhance cell cycle entry, without the increase of adhesion, in uninvolved, 
but not normal keratinocytes, even in the absence of T cell lymphokines (77). The main FN 
receptor α5β1 integrin was found to be overexpressed in NL psoriatic epidermis relative to 
normal epidermis (17, 18). KGF together with fibronectin and α5β1 integrin was suggested to 
play a crucial role in the pathogenesis of psoriasis by influencing inflammation and keratinocyte 
hyperproliferation. We focus in particular on alterations in NL skin and the role of EDA+FN 
and KGF in the initiation and progression of psoriasis. 
Therefore, we aimed: 
§ To investigate the expression of KGF, FGFR2, EDA+FN and α5 integrin in healthy and NL 
psoriatic skin. 
§ To examine whether KGF has an effect on the EDA+FN and FN production in cultured 
fibroblasts, keratinocytes and HaCaT cells. 
§ To determine the expression of different splice forms of FGFR2 in fibroblasts, keratinocytes 
and melanocytes. 
§ To identify the signal transduction pathway(s) through which KGF may influence and 
modulate the expression of EDA+FN and FN in healthy and NL skin derived fibroblasts. 
§ To study the putative correlation between the activation of STAT1 in healthy, NL and L 
skin and PASI score of patients. 
§ To construct an in silico model based on transcriptional regulatory molecules combined 
with our in vitro results involving KGF and FN signaling.
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3. MATERIALS AND METHODS 
3.1. Skin biopsies 
Patients with moderate-to-severe chronic plaque type psoriasis and healthy volunteers 
(age 18-60 years) were enrolled into the study. Patients had a medication-free period of at least 
4 weeks of systemic and/or at least 2 weeks without local therapy. Participant informed consent 
was obtained prior surgical intervention. PASI score was determined for all patients by 
dermatologists. Samples were collected from 16 patients and 25 healthy volunteers for the 
experiments. Mechanical stress was induced by tape-stripping procedure, and then punch 
biopsies were taken from uninvolved skin of psoriatic patients (n=6) and from healthy (n=6) 
subjects from tape-stripped and non-treated skin area from the buttock area at 24 and 48 hours 
after treatment for all other experiments tissues without the introduction of mechanical stress 
were used. All tissue collection complied with the Guidelines of the Helsinki Declaration and 
was approved by the Regional and Institutional Research Ethics Committee (Approval 
No:2799, 3517). 
3.2. Cell culture 
Primary keratinocytes, melanocytes and fibroblasts were obtained from healthy 
participants or psoriatic patients by enzymatic digestion of skin biopsies according to a standard 
protocol. Briefly, skin specimens were first washed in Salsol A solution (Human Rt, Gödöllő, 
Hungary) supplemented with 2% antibiotic/antimycotic solution (Sigma-Aldrich). Skin 
samples were then cut into narrow strips and incubated in Dispase solution (Roche Diagnostics, 
Mannheim, Germany) overnight at 4°C.  The epidermis was subsequently separated from the 
dermis and incubated in 0.25% trypsin/0.02% EDTA (PAA, Pasching, Austria) for 5 min at 
37°C to achieve a single-cell epidermal suspension. Fibroblasts were obtained by incubating 
the dermis in Digestion Mix (27mg Collagenase, 12.5mg Hyaluronidase and 1mg 
Deoxyribonuclease/ 10ml DMEM medium) for 2h at 37°C. The cell suspensions were filtered 
through a 100 µm nylon mesh (BD Falcon, San Jose, CA, USA) and pelleted by centrifugation. 
Fibroblasts were grown in low glucose DMEM medium containing 5% FBS. 
Melanocytes were maintained in Mel-mix medium as previously described (78). Keratinocytes 
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were grown in keratinocyte serum-free medium (Gibco® Keratinocyte SFM Kit; Life 
Technologies, Copenhagen, Denmark). HaCaT cells were kindly provided by Prof N.E. Fusenig 
and cultured in high-glucose DMEM medium containing 10% FBS. All media was 
supplemented with 1% antibiotic/antimycotic (PAA) and 1% L-glutamine solution (PAA). 
Fibroblasts, keratinocytes, melanocytes, and HaCaT cells were cultured at 37°C and 5% CO2 
in humidified conditions. Depending on cell growth, the medium was changed every 2–4 days 
and cells were passaged at 80% confluence. In our experiments, fibroblasts at passage number 
5, keratinocytes and melanocytes at passage 3 were used at 70% confluence.  
Fibroblasts, keratinocytes and HaCaT cells were cultured in 6-well plates at a starting 
density of 200,000 cells/well and incubated with 25 ng/mL KGF (ProSpec -Tany TechnoGene 
Ltd., Rehovot, Israel) for 24 h; untreated cells were used as controls. For KGF signaling 
pathway blocking experiments the following inhibitors were used: MEK1 inhibitor (PD98059, 
20µM), AKT ½ kinase inhibitor (10µM), STAT1 inhibitor (Epigallocatechin gallate, 40µM) 
and STAT3 inhibitor (Stattic, 4µM), all provided by Sigma-Aldrich, concentrations were 
applied	as previously described (79-81).		The pictures were taken using a Nikon Eclipse TS100 
inverted microscope (Nikon Incorporation, Melville, USA). 
3.3. RNA extraction and real-time quantitative reverse transcription polymerase 
chain reaction (RT qRT-PCR)  
For RNA isolation fibroblasts, melanocytes and keratinocytes were	 cultured as 
described above. Cells on 6 well plates were washed once with PBS, then harvested with 0.5 
ml TRIzolTM Reagent (Life Technologies). Total RNA was isolated according to the 
manufacturer`s instructions. RNA concentration was determined from A260 values. All RNA 
was treated with DNA-free™ reagents (Life Technologies). cDNA was synthesized from 1 µg 
total RNA with the iScript cDNA Synthesis Kit (Bio-Rad Laboratories, Hercules, CA, USA)	
according to the manufacturer’s protocol.	 
For EDA+FN qPCR amplification iQTM Supermix (from Bio-Rad Laboratories 
Hercules, CA, USA) was used. The EDA+FN primers were constructed as described previously 
(82). The amplification protocol for EDA+FN qPCR was the following: 95°C for 3 min, and 
then 95°C for 15 s and 56°C for 30 s, repeated 40 times.  
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FN and 18S rRNA amplifications were carried out with FastStart TaqMan Probe 
Mastermix (Roche Basel, Switzerland) using the following primers: FN forward	 5’-
GGAAAGTGTCCCTATCTCTGATACC-3’, reverse 5’-AATGTTGGTGAATCGCAGGT-
3’, probe: #33. 18S RNA forward 5’-CTCAACACGGGAAACCTCAC-3’, reverse 5’-
CGCTCCACCAACTAAGAACG-3’, probe: #77 (probes were from the Roche Universal 
Probe Library). Primers were designed using Probefinder for the Universal Probe Library 
system (Roche Diagnostics, Basel, Switzerland). FN and 18S rRNA amplifications were carried 
out under the following conditions: 95°C for 3 min, and then 95°C for 15 s and 57°C for 1 min, 
repeated 40 times.  
For FGFR2-IIIb and FGFR2-IIIc, specific custom TaqMan primer/probe sets (Life 
Technologies, Carlsbad, CA, USA) were developed	 as described previously (83) and for 
amplification the following protocol was used: 95°C for 10 min, and then 95°C for 15 s and 
60°C for 1 min, repeated 40 times.  
RT-PCR experiments were carried out on the LightCycler® 480 System Real-Time 
PCR machine (Roche Cobas Z 480 Roche Diagnostics). The abundance of each gene products 
was normalized to the 18S rRNA gene expression in each examined sample. Relative mRNA 
levels were calculated by the 2-ΔΔCt method. Data are expressed as arbitrary units proportional 
to the mRNA level. 
3.4. Immunofluorescent and immunohistochemistry staining 
Human punch biopsies were frozen embedded, stored at -80 °C, then cut into 6 µm 
sections. Samples were fixed in Fixation/Permeabilization Concentrate and Diluent 
(eBioscience, San Diego, CA) and washed in PBS. The sections were incubated for 30 min in 
1% goat serum in PBS (Sigma-Aldrich, St. Louis, MO, USA). The following primary 
antibodies were used: FGFR2 (1:100, Bek (C-17), Santa Cruz Biotechnology, Santa Cruz, CA), 
KGF (1:500, FGF-7 (N-14), Santa Cruz Biotechnology), α5 integrin (1:200, Becton-Dickinson, 
Franklin Lakes, NJ, USA), EDA+FN (1:500, clone IST9, Abcam, Cambridge, UK), and 
pSTAT1(Ser727), pSTAT1 (Tyr701), (both 1:400, Cell Signaling Technology, Beverly, MA) 
overnight at 4°C. Goat anti-rabbit IgG-Alexa Fluor 488, donkey anti-goat IgG-Alexa Fluor 546, 
goat anti-mouse IgG-Alexa Fluor 647 and Alexa Fluor 546 were used as secondary antibodies 
(all 1:500, from Life Technologies, Carlsbad, CA) for 2 h, at room temperature. Sections were 
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incubated without the primary antibody or with isotype control antibody for negative staining 
controls. Nuclei were stained with DAPI (Sigma-Aldrich). 
For immunohistochemistry paraffin embedded section of the three different skin types 
(mentioned above) were applied at 5 µm thickness and the ABC kit for the appropriate primary 
antibody (Enzo Life Sciences Inc.) was used according to the guidelines of the manufacturer to 
develop immunostaining. The counterstain of the cytoplasm and the nuclei was achieved by 
applying haematoxylin staining.  
Cultured human fibroblasts, keratinocytes and HaCaT cells were collected after brief 
trypsinization (0.25% trypsin solution, Sigma Aldrich) and centrifuged onto a slide using a 
cytocentrifuge (Cytopro™, Wescor, Logan, UT, USA), then fixed in 2% paraformaldehyde 
(Sigma-Aldrich). Stainings were carried out, as described above. Images were documented with 
a Zeiss AxioImager Z1 fluorescence microscope (Carl Zeiss Microscopy GmbH, Munich, 
Germany) equipped with an AxioCam MRm camera and AxioCam MRc camera for 
transmission light (bright field). Image processing and data analysis were conducted using ZEN 
2012 Microscope and Imaging or ImageJ software. 
3.5. Flow cytometry 
Cells were harvested as described, above fixed in Fixation/Permeabilization 
Concentrate and Diluent (eBioscience) and resuspended in PBS. Primary antibodies anti-
EDA+FN (1:500, clone IST9, Abcam), anti-FN (1:1000, clone IST4, Sigma-Aldrich) were 
applied for 45 min. Mouse IgG1 isotype antibody (Sigma-Aldrich) was used, for negative as 
control. Cells were then washed in PBS, and incubated with secondary antibodies as described 
above. Samples were analysed on a FACS Calibur flow cytometer equipped with 488 and 633 
nm lasers (Becton–Dickinson). Data was analysed using CellQuest Pro. 
3.6. Statistical analysis 
For statistical analysis, Repeated Measures Friedman ANOVA, Wilcoxon or one-way 
ANOVA were used.	 Multiple comparisons were done with SigmaPlot software (Systat 
Software Inc., Chicago, IL, USA). A probability test was used to test for normality, P≤0.05 was 
considered significant. 
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3.7. Bioinformatics analysis and model construction 
STRING, KEGG database and Reactome were used as a source to create protein-protein 
interactions and signaling pathways; SABiosciences’ transcription factor binding site data and CisRED 
(p<0.001) were applied for modeling protein-DNA interactions. Direction of transcriptional regulation 
was assessed with expression correlation matrix. Data of a microarray study with 48 dermal fibroblast 
samples carried out by Gabig-Cimińska et al. was downloaded from Gene Expression Omnibus. Probe 
with the largest interquartile range (IQR) was selected for genes with multiple probes. Coexpressional 
matrix was constructed using MATLAB R2014b (MathWorks Inc., Natick, MA). The genes and 
proteins related to KGF signaling, fibronectin-signaling, splicing and the regulation of these genes were 
collected (summarized in Table 1) and used for filtered matrix construction (Table 2). We used Pearson 
correlation coefficients with p values under 0.05 for the assessment of the direction of transcriptional 
regulation. If the correlation coefficient was positive it was considered an upregulation, and if it was 
negative, down regulation was defined. 
TARGET GENES TRANSCRIPTION FACTORS 
STAT1 STAT5b AP-1   
STAT3       
STAT5a AP-1     
STAT5b AP-1     
FN STAT3 AP-1   
FGF7 STAT3 AP-1   
FGFR2 AP-1 SOX9   
MAP2K1 STAT3     
AKT1       
AKT2 AP-1 STAT3   
AKT3       
ITGA5 AP-1     
FOXO1 AP-1     
FOS STAT1     
FOSb       
JUN STAT5a     
JUNb AP-1     
JUNd       
JDP2       
ATF1 ATF2     
ATF2 ATF2     
ATF3 AP-1     
ATF4 AP-1 ATF2 ATF6 
ATF5       
ATF6 ATF6     
ATF6b       
ATF7       
Table 1. List of genes applied for the construction of the co-expression matrix gene model. 
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4. RESULTS 
4.1. Altered protein expression of α5 integrin, EDA+FN, KGF and FGFR2 in 
psoriatic NL skin 
Healthy skin and psoriatic NL skin were investigated for differences in the expressions 
of α5 integrin, EDA+FN, KGF and FGFR2 before and 24, 48 hours after tape stripping. 
Immunofluorescent staining revealed a striking difference in all protein expressions examined 
even without tape stripping between normal and psoriatic NL skin (Figure 6). Mild mechanical 
stress introduced by tape stripping of the skin did not lead to any obvious changes in α5 integrin, 
EDA+FN, KGF and FGFR2 expressions or distributions at 24 and 48 hours after treatment in 
NL skin. In healthy control sections a slight increase in all protein expression was observed 
based on immunostaining (Figure 7). 
 
 
 
Figure 6. Increased expression of α5 integrin, EDA+FN, KGF and FGFR2 in NL skin without mechanical 
stress stimuli. Immunofluorescent analysis of α5 integrin, EDA+FN, KGF and FGFR2 expression in H (healthy) 
and NL (non-lesional) skin (n=6). Bar: 50 µm 
H H NL NL 
a b 
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Figure 7. Mild mechanical stress induced by tape stripping has no effect on the expression of α5 integrin, 
EDA+FN, KGF or FGFR2 in NL psoriatic skin and only a mild effect on healthy skin. The protein expression 
of α5 integrin (a), EDA+FN (b), KGF (c) and FGFR2 (d) was visualized by immunofluorescent staining 24 and 48 
hours following tape stripping in H (healthy) and in NL (non-lesional) skin. Bar: 50 µm. 
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4.2. Determining temporal changes in protein production for downstream analysis 
The production of EDA+FN is the highest after 24 hours, whereas the expression of FN and 
FGFR2 remains similar in the first 48 hours starting at both 40% and 70% confluence of normal 
human fibroblast 
FN, EDA+FN and FGFR2 protein levels were examined using flow cytometry at 6, 12, 
24, 36 and 48 hours in two different states of confluence (40% and 70%) of normal human 
fibroblasts. FN protein level showed an increasing tendency with time and peaked at 36h 
however this change did not reach the level of significance. In both 40% and 70% confluence 
states EDA+FN protein level was significantly elevated at 24h compared to any other measured 
time points. FGFR2 protein level did not show any change during the first 48h. Protein 
production was similar at both 40% and 70% confluence in the examined timeframe (Figure 
8). 
 
 
 
 
Figure 8. Flow cytometry measurement of FN, EDA+FN and FGFR2 protein levels at 6, 12, 24, 36 and 48 
hours at 40% and 70% of confluence of normal human fibroblasts. MFI: mean fluorescence intensity. Data 
are represented as mean±SD (n=3), ∗∗ p< 0.01. 
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4.3. KGF treatment of healthy human fibroblasts leads to the elevation of 
EDA+FN production 
EDA+FN and KGF are known to stimulate keratinocyte proliferation. KGF induces the 
expression of the major FN cell surface receptor α5β1 integrin. Given the differences in 
EDA+FN and KGF protein levels in healthy and NL psoriatic skin, we set out to investigate a 
putative regulatory connection between these two molecules. Exogenous treatment of cultured 
healthy fibroblasts with KGF for 24 hours increased the level of the EDA+FN splice variant, 
but not the total FN protein based on immunostaining and flow cytometry measurements 
(Figure 9 a, b). A similar increase in the EDA+FN mRNA level was detected, while the total 
FN mRNA remained unchanged (Figure 9 c).  We also investigated this effect of KGF on 
normal human keratinocytes and on the keratinocyte cell line, HaCaT. As expected, 
keratinocytes and HaCaT cells expressed the FN and the EDA+FN at a very low level compared 
to fibroblasts (Figure 10). However, upon in vitro KGF treatment these cells did not display 
detectable changes in mRNA and protein expressions of EDA+FN and total FN (Figure 10 a-c).  
 
 
29		
 
Figure 9. The expression of EDA+FN is induced by KGF in normal human fibroblasts. KGF treated 
fibroblasts and the change in expression in FN and EDA+FN at 24 hours. a) Immunofluorescent detection of 
EDA+FN. b) Flow cytometry measurement of EDA+FN and FN levels following KGF treatment. RFI: relative 
fluorescence intensity. c) FN or EDA+FN mRNA expression following KGF stimulation. Values are expressed in 
arbitrary units. Con: control. Data represent the mean±SEM (n=6). Bar: 50 µm. 
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Figure 10. Exogenous KGF treatment has no effect on EDA+FN expression of keratinocytes and HaCaT 
cells.  The expression of EDA+FN was visualized by immunostaining (a), its protein amount was quantified by 
flow cytometry (b) and mRNA expression was determined by real-time RT-PCR measurements (c) following 24 
hours of 25 ng/ml KGF treatment of healthy human keratinocytes and HaCaT cells. RFI: relative fluorescence 
intensity. Values are expressed in arbitrary units. Bar: 50 µm. 
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4.4. Expression of FGFR2 splice variants in fibroblasts, melanocytes and 
keratinocytes 
Two splice variants have been identified for FGFR2 designated as FGFR2-IIIb and 
FGFR2-IIIc that have different ligand binding preferences. These results were based on mitotic 
activity measurements (39). KGF has been shown to act on the FGFR2-IIIb variant increasing 
cellular proliferation (37). We determined the expression of the splice variants in healthy 
fibroblasts, melanocytes and keratinocytes using specific primers designed for RT-PCR, 
revealing that melanocytes and keratinocytes expressed the FGFR2-IIIb only, while fibroblasts 
mainly expressed the FGFR2-IIIc variant (Figure 11 a, b). 
 
 
Figure 11. Human fibroblasts in culture mainly express the FGFR2-IIIc, while melanocytes and 
keratinocytes the FGFR2-IIIb splice variant of FGFR2. a) RT-PCR products specific for FGFR2-IIIb and –
IIIc were run on a 2% agarose gel of cultured human fibroblasts (FB), melanocytes (MC) and keratinocytes. b) 
FGFR2 mRNA expression by fibroblasts for the two investigated splice variants detected by real-time RT-PCR. 
Values are expressed in arbitrary units. 
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4.5. MAPK signaling is involved in the regulation of EDA+FN controlled by KGF 
in healthy fibroblasts 
FGF signals (including KGF) are coordinated by four major pathways: the RAS-RAF-
MAPK, the PI3-AKT, the STAT and the PLCγ signaling (38, 44). In order to get a better insight 
into the modulation of FN expression by KGF in cultured fibroblasts derived from healthy skin, 
we performed blocking experiments targeting key molecules of the signal transduction 
pathways using specific inhibitors available for MEK1 (MAPK), AKT1/2 (PI3-AKT), STAT1 
and STAT3 (STAT) either alone or in combination. After 24h of inhibitory treatment the 
expressions of FN and EDA+FN were determined by flow cytometry and RT-PCR. The KGF 
induced EDA+FN elevation was abolished by the inhibition of MEK1 and returned to the level 
of control fibroblasts (Figure 12 a). In contrast, blocking AKT1/2 did not have an effect on 
EDA+FN protein expression (Figure 12 c). The inhibition of STAT1 or STAT3 did not 
influence KGF-mediated changes in EDA+FN levels, however, impairing these signaling 
molecules resulted in a KGF independent elevation of both FN and EDA+FN protein levels that 
was significant in the case of STAT1 inhibition (Figure 12 b).  
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Figure 12. KGF influenced elevation of the EDA+FN is mediated through MAPK. Exogenous KGF treatment 
triggered increase of EDA+FN and FN is not influenced by STAT1, STAT3 or AKT1/2 inhibition. a) FN and 
EDA+FN levels of healthy fibroblasts treated with KGF alone or in combination with MEK1 inhibitor. b) 
Following treatment of healthy fibroblasts with KGF alone or produced by in combination with inhibitors for 
STAT1, STAT3 or both. c) The level of EDA+FN and FN was measured by flow cytometry following 24h of KGF 
incubation with or without AKT1/2 inhibitor. Untreated cells or treated with the MEK1, AKT1/2, STAT1 and 
STAT3 inhibitor alone were used as controls. Data represent the mean±SEM (n=6). RFI: relative fluorescence 
intensity. 
4.6. Inhibition of the RAS-RAF-MAPK, PI3-AKT and STAT signaling pathways 
affect fibroblast viability 
Next we investigated the effect of blocking the three main signaling pathways (RAS-
RAF-MAPK, PI3-AKT and STAT) in fibroblasts using the STAT1, STAT3, MEK1 and AKT 
1/2 inhibitors.  Cell viability was examined after 24 hours of inhibition by microscopy (based 
on cellular morphology). Viable cell numbers showed large degree of reduction following 
STAT1-STAT3, STAT1-STAT3-MEK1 or STAT1-STAT3-AKT1/2 combined treatments 
(Figure 13). Using STAT1 or STAT3 inhibitors separately did not influence fibroblast viability 
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while blocking both STAT proteins simultaneously significantly decreased the survival of 
fibroblasts however further inhibition of AKT and MAPK pathways did not increase cell death. 
 
 
 
Figure 13. Combined blocking of the RAS-RAF-MAPK, PI3-AKT and STAT signaling pathways result in 
fibroblast cell death. Healthy fibroblasts were detected by microscope following 24h treatment with STAT1, 
STAT3 alone or in combination with inhibitors for MEK1, AKT1/2 or both. Ten-fold magnification. Con: control, 
STAT1i: STAT1 inhibitor, STAT3i: STAT3 inhibitor, MEK1i: MEK1 inhibitor, AKT1/2i: AKT1/2 inhibitor. 
(n=3) 
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4.7. Abnormal STAT1 activation in psoriatic skin plays a role in the regulation of 
both FN and EDA+FN 
To investigate further, we compared FN and EDA+FN expressions between derived 
from fibroblasts healthy and psoriatic NL skin 24 hours after STAT1 or STAT3 inhibition in 
culture. In contrast to healthy controls, blockade of STAT1 did not lead to the elevation of total 
FN and the EDA+FN splice variant in fibroblasts from NL skin changes upon STAT3 
impairment were not significant (Figure 14 a).  
Therefore, we investigated the phosphorylation pattern of STAT1 at Tyr701 and Ser727 
positions that are known to be key amino acid modifications leading to dimerization and 
influencing activity. Immunofluorescent staining for the phosphorylated Ser727 was highest in 
lesional psoriatic skin, lower, but clearly detectable in healthy skin, whereas NL skin samples 
showed the lowest intensity. In two out of four investigated NL samples phosphorylation was 
undetectable (Figure 14 b). Staining for the phosphorylated Tyr701 showed a much less 
noticeable but similar pattern. In samples of patients where no serine phosphorylation was 
detected in the NL skin, the staining for the phosphorylated Tyr701 was also not visible in either 
NL or lesional areas. To elucidate whether differences observed in STAT1 activity among 
patients correlated with the severity of the disease, PASI scores of donor patients were 
compared. The patients whose NL skin was negative for phosphorylations of STAT1 had a 
lower PASI score (12.4 and 17.8), whereas low STAT1 activity in NL skin was associated with 
a higher PASI score (19.6 and 20).  
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b 
 
Figure 14. Altered STAT1 regulation of EDA+FN and FN expression in psoriasis. a) The effect of STAT1 and 
STAT3 inhibition on FN and EDA+FN in fibroblasts derived from healthy and non-lesional skin. b) 
Immunofluorescent analysis of STAT1 (Ser727) phosphorylation. H: healthy, NL: non-lesional, and L: lesional 
skin. Data represent the mean±SEM (n=6, n=4). RFI: relative fluorescence intensity. Bar: 50 µm. 
37		
Immunhistochemistry analysis revealed the presence of pSTAT1 (Ser727) in the both the 
epidermis and the dermis. STAT1 activity showed a strong correlation with PASI score.	High 
PASI scores (eg. 19.6) were typically coupled with intensive pSTAT1 (Ser727) staining in the 
lesional skin and in these patients, the NL skin also showed a slight STAT1 activity. In contrast, 
patients with low PASI score (eg. 9.8) nearly no STAT1 activity was detectable in the NL skin. 
Indicating that pSTAT1 (Ser727) activation of the NL skin and the PASI scores of patients 
decreased in parallel.	Activation of STAT1 Tyr (701) form decays rapidly and only in samples 
obtained from patient with high PASI score can be observed, where the presence of both 
phosphorylated forms is much more intensive (Table 3). We compared NL skin samples near 
and far from the lesion for the extent of activation for the two different pSTAT1 forms in order 
to test whether the lesional area has an effect on surrounding NL skin. It was assessed that 
STAT1 activity is independent from the distance from the lesion indicating a sharp border 
between the NL and lesional skin (Figure 15).	The figure 15. also shows that the strongest 
STAT1 activation is detected in psoriatic L skin.  
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Figure 15. STAT1 Ser727 phosphorylated form shows high degree of activation in lesional (L) skin, it is present 
to a lesser extent in healthy skin, while hardly detectable in non-lesional (NL) skin by immunohistochemistry. NL 
skin of high PASI patients include active STAT1 in contrast with NL skin of low PASI patients. (n=3) 
 
 
Table 3. Activation of the pSTAT1 Ser(727) and pSTAT1 Tyr(701) forms in epidermis and dermis of NL 
and L skin with PASI scores of 3 psoriatic patients. NL: non-lesional, and L: lesional skin, E: epidermis, D: 
dermis; + (red): high positivity, +/- (yellow): low positivity, - (green): negative 
 
39		
4.8. In silico model construction 
We constructed an in silico model based on our in vitro results involving KGF- and FN-
signaling and the underlying transcriptional regulation network (Figure 16., Table 1-2.). Our 
data already suggested the participation of MAPK signaling in KGF induced FN splicing. The 
generated co-expression matrix implied a potential role of peptidyl-prolyl cis–trans isomerase 
(PPIG), a protein important in both protein folding and splicing (84), which is regulated by 
MEK1 induced AP-1. Changes in MEK1 activity could lead to the modulation of FN splicing 
through PPIG resulting in elevated EDA+FN levels. Our model also indicated that STAT3 
negatively regulates the expression of MEK1. This suggested inhibitory effect of STAT3 on 
MEK1 may account for the increased EDA+FN production upon STAT inhibition. However, 
our model did not explain our data on the significant increase in EDA+FN and FN following 
STAT1 inhibition in normal fibroblasts. The schematic summary model of the KGF induced 
changes on FN based on our results and public databases (in vivo, in vitro and in silico) of 
normal skin is presented in Figure 17. 
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Figure 16. In silico model of KGF and FN signaling. Green arrow: positive transcriptional regulation; Red arrow 
with circle arrowhead: negative transcriptional regulation; Arrows with dashed lines: undetermined direction of 
regulation.  
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5. DISCUSSION 
Despite the massive amount of research on psoriasis the underlying cellular and 
molecular mechanisms are only partially understood. One of the important characteristics of 
psoriasis is that the seemingly healthy looking skin of patients already carries certain molecular 
and structural abnormalities, which are likely to serve as a microenvironment favouring the 
manifestation of the disease. Previous studies have mainly focused on the characterization of 
the lesional skin and on differences between NL and lesional skin. However, the examination 
and comparison of healthy and NL skin in order to gain more knowledge regarding the 
abnormal processes and properties of NL skin received much less attention. Therefore, we 
focused our research to study irregularities that are already present in the NL skin.  
Psoriatic lesions are characterized by hyperproliferation of keratinocytes, where KGF is 
known to play an important role. At the protein level both KGF and its receptor FGFR2 were 
demonstrated to be elevated in lesional skin compared to normal skin (85). An increased 
expression of both KGF and FGFR2 mRNA were also described by others in NL as well as in 
lesional tissue (85, 86). KGF stimulates keratinocyte proliferation and it influences terminal 
differentiation (40, 87). The only known source of KGF in the skin are fibroblasts, however 
keratinocytes can mediate KGF production in fibroblasts through IL-1(88, 89), establishing a 
double paracrine regulatory loop, controlled by the AP-1 subunits c-Jun and JunB and directing 
the regeneration of the epidermis and maintaining tissue homeostasis in the skin (90). It was 
reported that microRNA-125 (miR-125) is downregulated in psoriatic lesional tissue (91). miR-
125 is known to have a negative influence on keratinocyte proliferation, partially by 
downregulating FGFR2 expression and driving keratinocytes towards differentiation, which 
also includes a change in the production of different ECM components (91).  
Alterations of the ECM are also part of the pathogenesis of psoriasis and increasing 
body of evidence indicates that the ECM is equally important under both normal and 
pathological conditions. By interacting with cell surface receptors (i.e. integrins), the different 
ECM components provide mechanical and biochemical signals to cells, influencing cellular 
behavior, affecting cell growth, differentiation, survival and ECM remodelling. ECM defects 
have been observed in the NL skin including disruption of the laminin layer leading to impaired 
keratinocyte adhesion to the basement membrane associated with aberrant expression of α5β1 
integrin and EDA+FN on keratinocytes (18, 92-94). Overexpression of α5 integrin and EDA+FN 
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has already been reported in connection with psoriasis and our group demonstrated that one of 
the potential sources of EDA+FN in the psoriatic NL skin are activated keratinocytes (32). 
Another report on psoriatic NL skin has shown that EDA+FN was localized mainly at the 
epidermal-dermal junction (20). It is well established that α5 integrin and EDA+FN could play 
an important regulatory role in the abnormal epidermal homeostasis of psoriatic skin (18, 32), 
and more recent evidence suggests that EDA+FN could be crucial in activating immune cells 
(30, 95). The EDA motif encompasses two non-classical binding sites for α4β1 and α9β1 integrins 
(21), receptors present on the surface of T-cells (96, 97) that could enhance T cell migration 
and accumulation in EDA+FN containing tissues, such as the skin. Moreover, both resting and 
activated Th1 cells but not Th2 cells express EDA+FN. Interestingly, activated Th1 cells 
express lower amount of FN, but with a much higher EDA+FN/FN ratio then resting ones (95). 
EDA+FN induces proinflammatory cytokines encoding genes and matrix metalloproteinases in 
T cells similarly to lipopolysaccharides (30). The EDA+FN mediated promotion of 
inflammatory responses takes place through TLR4 stimulation and leads to the increased 
expression of the tumour necrosis factor (TNF)-α, IL-1β, interleukin-6 (IL-6) and interleukin-
12 (IL-12), interleukin-23 (IL-23) and interferon-α (IFN-α), contributing to Th1 and Th17 cell 
mediated cutaneous inflammation (98, 99). These cytokines enhance the expression of 
intracellular adhesion molecule-1 (ICAM-1), vascular cell adhesion molecule-1 (VCAM-1) and 
endothelial expression of E-selectin as well as further recruitment and invasion of T cells into 
the tissue (100). The newly recruited Th1 cells produce more EDA+FN thereby closing the 
vicious cycle. 
EDA+FN was also suggested to promote acute inflammation and brain injury following 
cerebral ischemia in mice (82). EDA+FN is normally absent in human plasma, however patients 
with chronic inflammation and ischemic stroke have high plasma EDA+FN. The abnormally 
regulated overproduction of EDA+FN in psoriatic fibroblasts may be responsible not only for 
maintaining a local chronic inflammation in the skin, but by influencing plasma levels that 
could play a role in the systemic inflammation that has been described recently in psoriasis 
(101).  The EDA+FN rich extracellular milieu in psoriatic skin could be crucial for maintaining 
the characteristic epidermal changes, as well as the chronic inflammation in psoriatic lesions 
(for review see (76, 102)). It has been reported that KGF stimulates EDA inclusion in a mouse 
mammary epithelial cell line (SCp2) (103). Although, the exact regulation of EDA+FN splicing 
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is not completely clear, it is known that TGF-β enhances EDA+FN production (104). Our in 
silico model on KGF and FN signaling corroborate our experimental results in suggesting the 
participation of MEK1 in KGF induced fibronectin splicing through peptidyl-prolyl cis–
trans isomerase (PPIG), a protein known to be important in protein folding and splicing (84) 
and regulated by MEK1 induced AP-1.  
Autocrine feedback of several different FGFs through FGFRs exists under both normal 
and pathological conditions (38, 39, 105). KGF exerts its effect mainly through FGFR2-IIIb, 
but also via FGFR2-IIIc and FGFR1 (37). Since both FGFR2 and FGFR1 can initiate MEK1 
signalling, KGF could potentially modulate fibronectin splicing in a similar autocrine manner 
as other FGFs, most likely either through FGFR2-IIIc or FGFR1(39, 106) in fibroblasts. 
However, the participation of other receptors cannot be excluded either and further research is 
needed to understand the exact mechanism through which KGF affects FN splicing. Direct 
blocking of EDA+FN seems less feasible as a therapeutic approach, as blocking KGF or its 
receptors (107).  
STAT1 is the founding member of the STAT family and it is activated by interferons 
(IFNs), and signaling from IL-27, IL-35 and TLRs (108). There is ample evidence implicating 
IFNγ in the pathomechanism of psoriasis. Aberrant signaling and transcription have been 
reported for psoriatic keratinocytes with regard to suppressor of cytokine signaling 1 (SOCS1), 
a negative regulator of IFNγ signaling (109), by supressing STAT1 and IRF-1 (110).  The 
activation of STAT1 by IFNγ induces SOCS3 expression and inhibits STAT3 signaling thereby 
suppressing Th17 development. On the other hand IL-6 and IL-23 stimuli leads to high SOCS1 
expression that inhibits the IFNγ-mediated STAT1 activation and blocks the Th1 direction of 
T-cell differentiation (111). In regulatory T (Treg) cells the absence of SOCS1 results in STAT1 
hyperactivation and an increased secretion of IFNγ and IL-17 (112). STAT1 mediates an anti-
viral and tumor-suppressor response, whereas STAT3 is known to be a protooncogene (113). 
STATs can form homo- or heterodimers that can activate different signaling pathways and 
regulate the expression of different sets of genes. Wan el at. have demonstrated that STAT1 
and STAT3 play opposing roles in regulating IFNγ expression in CD4+ T cells in vivo  during 
chronic lymphotic choriomeningitis infection. Similarly, the IL-21 mediated IFNγ and T-box 
21 (TBX21) are reciprocally regulated by STAT1 and STAT3. IL-21 mediated STAT1 
phosphorylation was increased in CD4+ cells from patients with STAT1 gain of function 
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mutations and in patients with autosomal dominant hyper-IgE syndrome. CD8+ T cell 
cytotoxicity and apoptosis of mantle cell lymphoma are induced by STAT1 following IL-21 
stimulation (114, 115). The IL-6-mediated activation of STAT1 is increased in STAT3 deficient 
mouse embryonic fibroblasts and the IFNγ-mediated STAT3 activation is enhanced in STAT1 
deficient mice highlighting the significance of the balance between STAT1 and STAT3 (116, 
117). The processes described above suggest that the STATs are important participants in the 
maintenance of normal host defence reactions and mechanisms. 
The complex role of STAT1 in immune regulation is apparent from animal studies 
showing that both STAT1-/- and IFNγ-/- mice are highly susceptible to experimental 
autoimmune encephalomyelitis (EAE) (118, 119). It has been demonstrated that in both 
multiple sclerosis (MS) and in the EAE model α5 integrin and FN could be responsible for the 
extensive vascular remodelling, characteristic for MS, that takes place during the 
presymptomatic phase in EAE (120). The regulatory connection between STAT1 and FN 
described in this paper may explain the more severe disease manifestation in STAT1-/- animals. 
STAT1 has diverse functions, it inhibits a wide range of genes and it is a functional transcription 
factor even in the absence of inducer-mediated activation. Among its major targets of negative 
regulation are genes encoding proteins involved in regulating the extracellular matrix: matrix 
metalloproteinases (MMPs), perlecan, bullosus phemphigoid antigen-1 (BPAG1)(121). 
Abnormalities in STAT1 level or activity has been linked to several pathological conditions i. 
e. STAT1 is activated in SLE and considered to be a major contributor to SLE-associated 
inflammation (122).  
As our results indicate, in normal homeostatic skin tissue a steady state of STAT1 
activation is present and this could be partially responsible for downregulating FN and EDA+FN 
production, since blocking STAT1 in normal fibroblasts results in enhanced production of FN 
and EDA+FN. We detected the absent suppressive function of STAT1 in psoriatic fibroblasts 
that could be crucial in the pathomechanism of psoriasis. Using a STAT1 decoy 
oligodeoxynucleotide (dODN)-containing ointment Wagner et al. were able to inhibit hapten-
induced contact hypersensitivity reaction in animal models, indicating that topical STAT1 
blockade could be a novel anti-inflammatory therapy in skin inflammation (123). Our data 
indicate that in psoriasis STAT1 inactivation characterizes the uninvolved skin, thus this type 
of therapy may well work as a symptomatic therapy for the lesional skin. These results may 
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help to design new specific therapeutic agents for the treatment of psoriasis that may be more 
effective and longer lasting in reducing symptoms of the disease, thereby improve the life 
conditions of psoriatic patients. STAT mutational analysis may have a place in future disease 
management. The application of STAT inhibitors in inflammatory diseases may have a great 
potential for future therapies.  
 
 
 
Figure 17. Schematic model of investigated molecules playing a role in KGF mediated EDA+FN production 
in healthy skin.  
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SUMMARY 
In psoriasis the NL skin already contains abnormalities that are likely to serve as a 
microenvironment favouring the manifestation of the disease. FN and its splice variant the 
EDA+FN are essential extracellular matrix proteins influencing major cellular processes and 
they are abnormally expressed in psoriatic skin. KGF is overexpressed in psoriatic lesional skin 
and contribute to keratinocyte hyperproliferation. Given their function, these molecules are 
likely to play a part in the pathomechanism of psoriasis, therefore, in this study we focused on 
investigating the production of KGF, FGFR2, FN and EDA+FN in healthy and NL psoriatic 
skin and studied the regulatory mechanisms involving KGF, FN and EDA+FN in fibroblasts. 
We observed that the psoriatic NL skin displays an overexpression of KGF, FGFR2, α5 
integrin and EDA+FN compared to healthy skin. KGF mildly induced only EDA+FN, but not 
FN expression in healthy fibroblasts. Our results revealed that KGF regulated EDA+FN 
production takes place in an autocrine manner through MAPK signaling. Based on these results 
we designed an in silico model to predict key players in a putative regulatory network 
explaining the effect of KGF on EDA+FN production. We provide in vitro evidence that STAT1 
negatively regulates both FN and EDA+FN expressions in healthy fibroblasts and this regulation 
is compromised in fibroblasts derived from NL psoriatic dermis. We detected active STAT1 in 
healthy and lesional skin, as reported previously, however, in the NL skin STAT1 activation 
was close to absent in samples irrespectively from the distance from lesions. 
These result led us to the conclusion that the production of FN, EDA+FN by fibroblasts 
and the signaling of STAT1 is abnormally regulated in the psoriatic NL skin, suggesting a 
crucial mechanism for keeping NL skin in a preactivated state for developing a chronic wound 
healing phenotype.  
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Summary
Background Data indicate that in psoriasis, abnormalities are already present in
nonlesional skin. Transforming growth factor-b and keratinocyte growth factor
(KGF), together with fibronectin and a5b1 integrin, were suggested to play a
crucial role in the pathogenesis of psoriasis by influencing inflammation and ker-
atinocyte hyperproliferation.
Objectives To investigate the expression of KGF, fibroblast growth factor receptor
(FGFR)2, fibronectin (FN) and extra domain A (EDA)-positive FN in healthy and
nonlesional psoriatic skin, and to study the effect of KGF on the regulation of FN
and EDA+FN production by fibroblasts.
Methods Healthy, nonlesional psoriatic skin and lesional psoriatic skin were
immunostained for a5 integrin, KGF, FGFR2, EDA+FN and signal transducer and
activator of transcription (STAT)1. KGF-treated cell cultures were analysed for FN
and EDA+FN mRNA and protein by real-time reverse-transcriptase polymerase
chain reaction and flow cytometry, respectively. The major downstream signalling
of KGF was investigated by blocking experiments using inhibitors of mitogen-acti-
vated protein kinase (MAPK) kinase (MEK1), AKT1/2, STAT1 and STAT3.
Results The expression of a5 integrin, EDA+FN, KGF and its receptor FGFR2 is
elevated in psoriatic nonlesional skin compared with healthy skin. KGF mildly
induced EDA+FN, but not FN expression in healthy fibroblasts through MAPK
signalling. Fibroblasts express the FGFR2-IIIc splice variant. STAT1 negatively reg-
ulates both FN and EDA+FN expression in healthy fibroblasts, and this regulation
is compromised in fibroblasts derived from nonlesional psoriatic dermis. We
detected active STAT1 in healthy and lesional skin, similarly to a previous report.
However, in the nonlesional skin STAT1 activation was absent in tissues far away
from lesions.
Conclusions The production of FN and EDA+FN by fibroblasts and the signalling of
STAT1 are abnormally regulated in psoriatic nonlesional skin.
What’s already known about this topic?
• In psoriasis, nonlesional skin already contains abnormalities as a base for the mani-
festation of the disease.
• Fibronectin (FN) and its splice variant EDA+FN are essential extracellular matrix
proteins influencing major cellular processes, and they are abnormally expressed in
psoriatic skin.
• Keratinocyte growth factor (KGF) is overexpressed in psoriatic lesional skin and
contributes to keratinocyte hyperproliferation.
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What does this study add?
• KGF and its receptor FGFR2 are overexpressed in psoriatic nonlesional skin. KGF
influences EDA+FN production in fibroblasts through MEK1 signalling.
• Fibroblasts express the FGFR2-IIIc splice variant of the FGFR2 receptor.
• STAT1 negatively regulates FN and EDA+FN production in normal cultured fibrob-
lasts, but not in fibroblasts derived from psoriatic nonlesional skin.
• STAT1 is active in healthy skin and psoriatic lesional skin, but not in nonlesional
psoriatic skin.
It is well known that psoriasis is an inflammatory skin disease in
which both innate and adaptive immune activation play an
essential role in the maintenance of the abnormal skin pheno-
type.1 However, it is less well known how much resident cells of
the tissue contribute to the pathology. A reasonable approach to
seek alterations in tissue responses in psoriasis is to investigate
the phenotypically normal-looking nonlesional psoriatic skin.
The main fibronectin (FN) receptor a5b1 integrin was found
to be overexpressed in nonlesional psoriatic epidermis compared
with normal skin.2,3 There is evidence that proper regulation of
integrin expression in keratinocytes is essential for normal epi-
dermal homeostasis, as shown by the suprabasal overexpression
of integrins in transgenic mice resulting in epidermal hyperpro-
liferation and inflammatory reaction.4 In the steady state of nor-
mal human adult epidermis, a5 integrin expression of
keratinocytes is downregulated. A possible explanation for a5
integrin overexpression in nonlesional skin is the presence of FN
and one of its isoforms, extra domain A-containing fibronectin
(EDA+FN), in the microenvironment of basal keratinocytes.3,5
Keratinocyte growth factor (KGF/FGF7) is a member of the
fibroblast growth factor (FGF) family produced by mesenchy-
mal cells and considered to be a major growth factor for ker-
atinocytes. Several reports suggest that KGF reduces the ability
of keratinocytes to initiate terminal differentiation and undergo
programmed cell death. Overexpression of KGF in the basal epi-
dermal cell layer of transgenic mice results in epidermal hyper-
plasia.6 There is also evidence suggesting that fibroblasts from
lesional and nonlesional skin of patients with psoriasis induce
keratinocyte outgrowth by producing soluble signals.7 More
recently, it has been reported that KGF can induce the expres-
sion of a5 integrin, and it delays the expression of keratin 10
and transglutaminase in keratinocytes.8 Indirect evidence, such
as measurement of mitogenic activity, suggests that the specific
receptor for KGF on epithelial cells is the IIIb splice variant of
fibroblast growth factor receptor (FGFR)2.9
According to our observations, psoriatic nonlesional skin dis-
plays a marked overexpression of KGF, FGFR2, a5 integrin and
EDA+FN compared with healthy skin. Therefore, in this study
we focused on investigating regulatory mechanisms involving
KGF and FN. Our results revealed that KGF regulates EDA+FN
production in an autocrine manner through mitogen-activated
protein kinase (MAPK) signalling in healthy fibroblasts. With
these results we designed an in silico model to predict a possible
regulatory network for the effect of KGF on EDA+FN produc-
tion. We provide in vitro evidence that both FN and EDA+FN are
negatively regulated by activated signal transducer and activator
of transcription (STAT)1 in healthy fibro-blasts, and this is in
contrast to psoriatic nonlesional skin-derived fibroblasts. Active,
phosphorylated STAT1 was found in healthy skin as well as in
psoriatic lesions, but not in psoriatic nonlesional skin, suggest-
ing a crucial mechanism for keeping nonlesional skin in a preac-
tivated state to developing a chronic wound-healing phenotype.
Materials and methods
Skin biopsies
Patients with moderate-to-severe chronic plaque-type psoriasis
and healthy volunteers (age 18–60 years) were enrolled into the
study. Patients had a medication-free period of ≥ 4 weeks with-
out systemic therapy and/or ≥ 2 weeks without local therapy.
Participant-informed consent was obtained prior to surgical inter-
vention. The Psoriasis Area and Severity Index (PASI) score was
determined for all patients by dermatologists. Samples were col-
lected from 16 patients and 25 healthy volunteers for the experi-
ments. Mechanical stress was induced by a tape-stripping
procedure, then punch biopsies were taken from uninvolved skin
of patients with psoriasis (n = 6) and healthy subjects (n = 6)
from a tape-stripped and nontreated (control) skin area from the
buttock area at 24 and 48 h after treatment (Fig. S1). For all other
experiments, tissues without the introduction of mechanical
stress were used. All tissue collection complied with the guideli-
nes of the Declaration of Helsinki and was approved by the Regio-
nal and Institutional Research Ethics Committee (2799, 3517).
Immunofluorescence staining
Human punch biopsies were frozen embedded, stored at
!80 °C, then cut into 6-lm sections. Samples were fixed in Fixa-
tion/Permeabilization Concentrate and Diluent (eBioscience, San
Diego, CA, U.S.A.) and resuspended in phosphate-buffered saline
(PBS). The sections were incubated for 30 min in goat serum
(Sigma-Aldrich, St Louis, MO, U.S.A.). The following primary
antibodies were used, overnight at 4 °C: FGFR2 [1 : 100, Bek
(C-17); Santa Cruz Biotechnology, Santa Cruz, CA, U.S.A.], KGF
[1 : 500, FGF-7 (N-14); Santa Cruz Biotechnology], a5 integrin
(1 : 200; Becton-Dickinson, Franklin Lakes, NJ, U.S.A.),
EDA+FN (1 : 500, clone IST9; Abcam, Cambridge, U.K.) and p-
STAT1(Ser727) and p-STAT1 (Tyr701) (both 1 : 400; Cell Sig-
naling Technology, Beverly, MA, U.S.A.). Goat antirabbit IgG-
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Alexa Fluor 488, donkey antigoat IgG-Alexa Fluor 546, goat anti-
mouse IgG-Alexa Fluor 647 and Alexa Fluor 546 were used as
secondary antibodies (all 1 : 500; Life Technologies, Carlsbad,
CA, U.S.A.) for 2 h at room temperature. Sections were incu-
bated without the primary antibody or with isotype control anti-
body for negative staining controls. Nuclei were stained with
DAPI (4ʹ,6-diamidino-2-phenylindole; Sigma-Aldrich).
Cultured human fibroblasts, keratinocytes and HaCaT cells
were collected after brief trypsinization (0"25% trypsin solu-
tion; Sigma-Aldrich) and centrifuged onto a slide using a cyto-
centrifuge (CytoproTM; Wescor, Logan, UT, U.S.A.), then fixed
in 2% paraformaldehyde (Sigma-Aldrich). Stainings were car-
ried out as described above. Images were documented with a
Zeiss AxioImager Z1 fluorescence microscope (Carl Zeiss
Microscopy GmbH, Munich, Germany) equipped with an
AxioCam MRm camera. Image processing and data analysis
were conducted using ZEN 2012 Microscope and Imaging
(Carl Zeiss) or ImageJ software (http://imagej.nih.gov/ij/).
Flow cytometry
Cells were harvested as described above, fixed in Fixation/Per-
meabilization Concentrate and Diluent (eBioscience) and
resuspended in PBS. Primary antibodies anti-EDA+FN
(1 : 500, clone IST9; Abcam) and anti-FN (1 : 1000, clone
IST4; Sigma-Aldrich) were applied for 45 min. Mouse IgG1
isotype antibody (Sigma-Aldrich) was used as the negative
control. Cells were then washed in PBS and incubated with
secondary antibodies as described above. Samples were anal-
ysed on a FACSCalibur flow cytometer equipped with 488-
mm and 633-nm lasers (Becton-Dickinson).
Statistical analysis
For statistical analysis, repeated-measures Friedman ANOVA,
Wilcoxon test or one-way ANOVA were used. Multiple compar-
isons were carried out with SigmaPlot software (Systat Soft-
ware Inc., Chicago, IL, U.S.A.). A probability test was used to
test for normality; P ≤ 0"05 was considered significant.
Further methods
Detailed information of the materials and methods regarding cell
culture experiments, real-time quantitative reverse-transcriptase
polymerase chain reaction (RT-PCR) and the in silico model are
presented in Appendix S1 (see Supporting Information).
Results
Altered protein expression of a5 integrin, extra domain
A-positive fibronectin, keratinocyte growth factor and
fibroblast growth factor receptor 2 in psoriatic
nonlesional skin
Healthy skin and psoriatic nonlesional skin were investigated
for differences in the expression of a5 integrin, EDA
+FN,
KGF and FGFR2 before and 24 and 48 h after tape strip-
ping. Immunofluorescence staining revealed a striking
difference in all protein expressions examined, even without
tape stripping, between normal and psoriatic nonlesional
skin (Fig. 1). Mild mechanical stress introduced by tape
stripping of the skin did not lead to any obvious changes
in a5 integrin, EDA
+FN, KGF or FGFR2 expression or
distribution at 24 and 48 h after treatment in nonlesional
skin. In healthy control sections a slight increase in all pro-
tein expression was observed based on immunostaining
(Fig. S1a–d).
Fig 1. Increased expression of a5 integrin, extra domain A-containing
fibronectin (EDA+FN), keratinocyte growth factor (KGF) and fibroblast
growth factor receptor (FGFR)2 in nonlesional skin without
mechanical stress stimuli. Immunofluorescence analysis of a5 integrin,
EDA+FN, KGF and FGFR2 in healthy (left column) and nonlesional
skin (right column) (n = 6). DAPI, 4ʹ,6-diamidino-2-phenylindole.
Bar: 50 lm.
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Keratinocyte growth factor treatment of healthy human
fibroblasts leads to the elevation of extra domain
A-positive fibronectin production
EDA+FN and KGF are known to stimulate keratinocyte prolif-
eration. KGF induces the expression of the major FN cell sur-
face receptor a5b1 integrin. Given the differences in EDA
+FN
and KGF protein levels in healthy and nonlesional psoriatic
skin, we set out to investigate a putative regulatory connection
between these two molecules. Exogenous treatment of cul-
tured healthy fibroblasts with KGF for 24 h increased the level
of the EDA+FN splice variant, but not the total FN protein,
based on immunostaining and flow cytometry measurements
(Fig. 2a, b). A similar increase in the EDA+FN mRNA splice
variant was detected, while the total FN mRNA remained
unchanged (Fig. 2c).
We also investigated this effect of KGF on normal human
keratinocytes and melanocytes and on the keratinocyte cell
line, HaCaT (Figs S2, S3). As expected, keratinocytes and
HaCaT cells expressed FN and EDA+FN at a very low level
compared with fibroblasts, while melanocytes expressed both
proteins at a comparable level with fibroblasts (Fig. S3). How-
ever, upon in vitro KGF treatment these cells did not display
detectable changes in mRNA and protein expression of
EDA+FN and total FN (Fig. S2).
Expression of fibroblast growth factor receptor 2 splice
variants in fibroblasts, melanocytes and keratinocytes
Two splice variants have been identified for FGFR2, designated
as FGFR2-IIIb and FGFR2-IIIc, which have different ligand-
binding preferences. These results were based on mitotic activ-
ity measurements.10 KGF has been shown to act on the
FGFR2-IIIb variant, increasing cellular proliferation.11 We
determined the expression of the splice variants on healthy
fibroblasts, melanocytes and keratinocytes using specific pri-
mers designed for RT-PCR, revealing that melanocytes and
keratinocytes expressed FGFR2-IIIb only, while fibroblasts
expressed mainly the FGFR2-IIIc variant (Fig. 3).
Mitogen-activated protein kinase signalling is involved in
the regulation of extra domain A-positive fibronectin by
keratinocyte growth factor receptor in healthy fibroblasts
Fibroblast growth factor signals (including KGF) are
coordinated by four major pathways: Ras-Raf-MAPK, phos-
(a)
(b)
(c)
Fig 2. The expression of extra domain A-
containing fibronectin (EDA+FN) is induced
by keratinocyte growth factor (KGF) in
normal human fibroblasts. KGF-treated
fibroblasts and the change in expression in
fibronectin (FN) and EDA+FN at 24 h. (a)
Immunofluorescent detection of EDA+FN. (b)
Flow cytometry measurement of EDA+FN and
FN levels following KGF treatment. RFI,
relative fluorescence intensity; con, control.
(c) FN and EDA+FN mRNA expression
following KGF stimulation. Values are
expressed in arbitrary units. Data represent the
mean # SEM (n = 6). DAPI, 4ʹ,6-diamidino-
2-phenylindole. Bar: 50 lm.
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phoinositide 3-kinase (PI3K)/Akt, STAT and phospholipase
Cc.12,13 In order to get a better insight into the modulation of
FN expression by KGF in cultured fibroblasts derived from
healthy skin, we performed blocking experiments targeting
key molecules of the signal transduction pathways using speci-
fic inhibitors available for MAPK kinase (MEK1) (MAPK path-
way), Akt1/2 (PI3K-Akt pathway), STAT1 and STAT3 (STAT
pathway) either alone or in combination. After 24 h of inhibi-
tory treatment the expression of FN and EDA+FN was deter-
mined by flow cytometry and RT-PCR. The KGF-induced
EDA+FN elevation was abolished by the inhibition of MEK1
and returned to the level of control fibroblasts (Fig. 4a). In
contrast, blocking Akt1/2 did not have an effect on EDA+FN
protein expression (Fig. S4). The inhibition of STAT1 or
STAT3 did not influence KGF-mediated changes in EDA+FN
levels (Fig. 4b). However, impairing these signalling mole-
cules resulted in a KGF-independent elevation of both FN and
EDA+FN protein levels that was significant in the case of
STAT1 inhibition (Fig. 4c).
Abnormal signal transducer and activator of transcription
1 activation in psoriatic skin plays a role in the
regulation of both fibronectin and extra domain
A-positive fibronectin
To investigate further, we compared the FN and EDA+FN
expressions between healthy and psoriatic nonlesional skin-
derived fibroblasts 24 h after STAT1 or STAT3 inhibition in cul-
ture. Changes upon STAT3 impairment were not significant;
however, blockade of STAT1 did not lead to the elevation of
total FN and EDA+FN in fibroblasts from nonlesional skin in
contrast to healthy controls (Fig. 4c). Therefore, we investi-
gated the phosphorylation pattern of STAT1 at Tyr701 and
Ser727, which are known to be key amino acid modifications
leading to dimerization and influencing activity.
Immunofluorescent staining for the phosphorylated Ser727
was highest in lesional psoriatic skin, and lower, but clearly
detectable, in healthy skin, whereas nonlesional skin samples
showed the lowest intensity. In two of four investigated non-
lesional samples phosphorylation was undetectable (Fig. 4d).
Staining for the phosphorylated Tyr701 showed a much less
noticeable but similar pattern. In samples of patients where no
serine phosphorylation was detected in the nonlesional skin,
staining for the phosphorylated Tyr701 was also not visible in
either nonlesional or lesional areas. To elucidate whether dif-
ferences observed in STAT1 activity among patients correlated
with the severity of the disease, PASI scores of donor patients
were compared. The patients whose nonlesional skin was neg-
ative for phosphorylations of STAT1 had lower PASI scores
(12"4 and 17"8), therefore we were able to take nonlesional
samples further away from lesions, at least 10-cm distance.
Patients with detectable but low STAT1 activity in nonlesional
skin had higher PASI scores (19"6 and 20).
In silico model construction
We constructed an in silico model based on our in vitro results
involving KGF and FN signalling and the resultant transcrip-
tional regulation network (Fig. 5 and Tables S1, S2). Our data
already suggested the participation of MAPK signalling in
KGF-induced FN splicing. The generated coexpression matrix
implied a potential role of peptidylprolyl cis–trans isomerase G
(PPIG), a protein important in both protein folding and splic-
ing,14 which is regulated by MEK1-induced activating protein
(AP)-1. Changes in MEK1 activity could lead to modulation of
FN splicing through PPIG, resulting in elevated EDA+FN
levels.
Our model also indicates that STAT3 negatively regulates
the expression of MEK1. This suggested inhibitory effect of
STAT3 on MEK1 may account for the increased EDA+FN pro-
duction upon STAT inhibition. However, our model did not
explain our data showing a significant increase in EDA+FN
and FN following STAT1 inhibition in normal fibroblasts. The
schematic summary model of KGF-induced changes on FN
based on our results in normal skin (in vivo, in vitro and in silico)
is presented in Figure 6.
Discussion
One of the major characteristics of psoriatic lesional skin is
the hyperproliferation of keratinocytes, where KGF is known
to play an important role. At the protein level both KGF and
FGFR2 were demonstrated to be elevated in lesional skin com-
pared with normal skin.15 At the mRNA level in both nonle-
sional and lesional tissue, increased expression of both KGF
(a)
(b)
Fig 3. Human fibroblasts in culture express mainly fibroblast growth
factor receptor (FGFR2)-IIIc, while melanocytes and keratinocytes
express the FGFR2-IIIb splice variant of FGFR2. (a) Reverse-
transcriptase polymerase chain reaction (RT-PCR) products specific for
FGFR2-IIIb and IIIc were run on a 2% agarose gel of cultured human
fibroblasts (FB), melanocytes (MC) and keratinocytes (KC). (b) FGFR2
mRNA expression by fibroblasts for the two investigated splice
variants detected by real-time RT-PCR. Values are expressed in
arbitrary units.
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and FGFR2 transcripts was also described by others.16,17 KGF
stimulates keratinocyte proliferation and influences terminal
differentiation.6,17 The only known source of KGF in the skin
is fibroblasts, and keratinocytes can mediate KGF production
in fibroblasts through interleukin (IL)-1,18,19 establishing a
double paracrine regulatory loop, controlled by AP-1 subunits
c-Jun and JunB, and directing the regeneration of the epider-
mis and maintaining tissue homeostasis in the skin.20 It was
reported that the microRNA miR-125 is downregulated in
psoriatic lesional tissue. miR-125 is known to have a negative
influence on keratinocyte proliferation, partially by downregu-
lating FGFR2 expression and driving keratinocytes towards dif-
ferentiation.21
Integrins and their corresponding extracellular ligands also
influence cell proliferation and differentiation.22 Overexpres-
sion of a5 integrin and EDA+FN has already been reported in
connection with psoriasis, and our group demonstrated that
one of the potential sources of EDA+FN in nonlesional psori-
atic skin is activated keratinocytes.23 Another report on nonle-
sional skin has shown that EDA+FN was localized mainly at
the dermoepidermal junction.5 It is well established that a5
integrin and EDA+FN could play an important regulatory role
in the abnormal epidermal homeostasis of psoriatic skin,3,23
and more recent evidence suggests that EDA+FN could be cru-
cial in activating immune cells.24,25 The EDA motif encom-
passes two nonclassical binding sites for a4b1 and a9b1
integrins,26 receptors present on the surface of T cells27,28 that
could enhance T-cell migration and accumulation in EDA+FN-
containing tissues, such as the skin.
EDA+FN promotes acute inflammation and brain injury fol-
lowing cerebral ischaemia in mice.29 EDA+FN is normally
absent in human plasma; however, patients with chronic
inflammation and ischaemic stroke have high plasma EDA+FN.
The abnormally regulated overproduction of EDA+FN in psori-
atic fibroblasts may not only be responsible for maintaining a
local chronic inflammation in the skin, but may also influence
plasma levels that could play a role in the systemic inflamma-
tion that has been reported recently in psoriasis.30 The
EDA+FN-rich extracellular milieu in psoriatic skin could be
(a)
(b)
(c)
(d)
Fig 4. Keratinocyte growth factor (KGF)-influenced elevation of extra
domain A-containing fibronectin (EDA+FN), mediated through
mitogen-activated protein kinase (MAPK) signalling, and altered signal
transducer and activator of transcription (STAT)1 regulation of
EDA+FN and fibronectin (FN) expression in psoriasis. (a) FN and
EDA+FN levels of healthy fibroblasts treated with KGF alone or in
combination with a MAPK kinase (MEK1) inhibitor. (b) Following
treatment of healthy fibroblasts with KGF alone or in combination
with inhibitors of STAT1, STAT3 or both. (c) The effect of STAT1 and
STAT3 inhibition on FN and EDA+FN in fibroblasts derived from
healthy (H) and nonlesional (NL) skin. (d) Immunofluorescent
analysis of STAT1 Ser727 phosphorylation. L, lesional skin. Data
represent the mean # SEM (n = 6). RFI, relative fluorescence
intensity; DAPI, 4ʹ,6-diamidino-2-phenylindole. Bar: 50 lm.
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crucial for maintaining the characteristic epidermal changes, as
well as the chronic inflammation in psoriatic lesions.31,32
It has been reported that KGF stimulates EDA inclusion in a
mouse mammary epithelial cell line (SCp2).33 Although the
exact regulation of EDA+FN splicing is not completely clear, it
is known that TGF-b enhances EDA+FN production.34 Our in
silico model of KGF and FN signalling corroborates our experi-
mental results in suggesting the participation of MEK1 in
KGF-induced FN splicing through PPIG, a protein known to
be important in protein folding and splicing14 and regulated
by MEK1-induced AP-1.
Autocrine feedback of several different FGFs through FGFRs
exists under both normal and pathological conditions.10,13,35
KGF exerts its effect mainly through FGFR2-IIIb, but also via
FGFR2-IIIc and FGFR1.11 As both FGFR2 and FGFR1 can initi-
ate MEK1 signalling, KGF could potentially modulate FN splic-
ing in a similar autocrine manner to other FGFs, most likely
either through FGFR2-IIIc or FGFR110,36 in fibroblasts. How-
ever, the participation of other unknown receptors also cannot
be excluded, and further research is needed to understand the
exact mechanism through which KGF affects FN splicing.
Directly blocking EDA+FN seems less feasible as a therapeutic
approach compared with blocking KGF or its receptors.37
STAT1 is the founding member of the STAT family and
is activated by interferons (IFNs), and signalling from IL-27,
IL-35 and Toll-like receptors.38 There is ample evidence
Fig 5. In silico model of keratinocyte growth
factor (KGF) and fibronectin (FN) signalling.
Green arrow, positive transcriptional
regulation; red arrow with circle arrowhead,
negative transcriptional regulation; arrows
with dashed lines, undetermined direction of
regulation. FGFR, fibroblast growth factor
receptor; ITGA, integrin alpha; MEK1,
mitogen-activated protein kinase kinase; PPIG,
peptidylprolyl cis–trans isomerase G; SDC,
syndecan; STAT, signal transducer and
activator of transcription.
Fig 6. Schematic model of investigated
molecules playing a role in keratinocyte
growth factor (KGF)-mediated extra domain
A-containing fibronectin (EDA+FN)
production in healthy skin. FGFR, fibroblast
growth factor receptor; MAPK, mitogen-
activated protein kinase; MEK, MAPK kinase;
STAT, signal transducer and activator of
transcription.
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implicating IFN-c in the pathomechanism of psoriasis.39 Aber-
rant signalling and transcription have been reported for psori-
atic keratinocytes with regard to SOCS1 (suppressor of
cytokine signalling 1), a negative regulator of IFN-c sig-
nalling,40 and also for STAT1 and interferon-regulated factor
1.41 The complex role of STAT1 in immune regulation is
apparent from animal studies showing that both STAT1!/!
and IFNc!/! mice are highly susceptible to experimental
autoimmune encephalomyelitis (EAE).42,43 It has been demon-
strated in both multiple sclerosis and in the EAE model that
a5 integrin and FN could be responsible for the extensive vas-
cular remodelling, characteristic for MS, that takes place dur-
ing the presymptomatic phase in EAE.44
The regulatory connection between STAT1 and FN
described in this article may explain the more severe disease
manifestation in STAT!/! animals. STAT1 has diverse func-
tions: it inhibits certain genes and is a functional transcription
factor even in the absence of inducer-mediated activation.
Among its major targets of negative regulation are genes
encoding proteins involved in regulating the extracellular
matrix: matrix metalloproteinases, perlecan and bullous pem-
phigoid antigen-1.45 As our results indicate, in normal home-
ostatic skin tissue, a steady state of STAT1 activation is
present, and this could be partially responsible for downregu-
lating FN and EDA+FN production, as blocking STAT1 in nor-
mal fibroblasts results in enhanced production of FN and
EDA+FN. The absent suppressive function of STAT1 in psori-
atic fibroblasts could be crucial in the pathomechanism of pso-
riasis. Using a STAT1 decoy oligodeoxynucleotide-containing
ointment Wagner et al. were able to inhibit hapten-induced
contact hypersensitivity reaction in animal models, indicating
that topical STAT1 blockade could be a novel anti-inflamma-
tory therapy in skin inflammation.46 Our data indicate that in
psoriasis STAT1, inactivation characterizes the uninvolved skin;
thus, this type of therapy may well work as a symptomatic
therapy for lesional skin.
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Abnormális STAT1 aktivitás pikkelysömörben
Abnormal STAT1 activation in psoriasis
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ÖSSZEFOGLALÁS
A STAT (signal transducer and activator of transcripti-
on) jelátviteli útvonalak kulcsfontosságú szerepet töltenek
be a pikkelysömör patomechanizmusában. Kutatócsopor-
tunk megállapította, hogy a STAT1 aktivált állapotban
van egészséges és tünetes bôrben, ellentétben a tünetmen-
tes bôrrel, ahol jórészt inaktív. Tünetmentes bôrben a
csökkent mértékû STAT1 aktiváció független a lézióktól
való távolságtól. Az aktivált STAT1 korrelációt mutat a
PASI (psoriasis area and severity index) értékével, minél
magasabb a beteg PASI-ja, annál erôsebb az aktivált
STAT1 kifejezôdése a bôrben. Korábbi vizsgálataink azt
mutatták, hogy a STAT1 abnormálisan regulálódik a pik-
kelysömörös fibroblasztokban. Ezek az eredmények felve-
tik annak lehetôségét, hogy a STAT1 új terápiás célpont
lehet a betegségben.
Kulcsszavak: 
pikkelysömör - STAT1 -  tünetmentes bôr
SUMMARY
The STAT (signal transducer and activator of
transcription) signalling pathway plays a key role in the
pathogenesis of psoriasis. Our results indicate that STAT1
is active in both healthy and in psoriatic lesional skin and
in contrast to the non-lesional skin where it is mainly
inactive. The distance from the lesion does not affect
STAT1 activity in the non-lesional skin. The STAT1
activation correlates with the PASI (psoriasis area and
severity index) of psoriatic patients. In our previous work
we have shown that STAT1 is abnormally regulated in
psoriatic fibroblasts. These data indicate that STAT1
could be a potential new target for the therapy of the
disease.
Key words: 
psoriasis - STAT1- non-lesional skin
A pikkelysömör egy multifaktoriális, krónikus bôrbe-
tegség, amelynek kialakulásában és fenntartásában mind
a veleszületett, mind az adaptív immunitás szerepet ját-
szik (1). A pikkelysömörös bôrben az epidermális kerati-
nociták túlzott proliferációja és abnormális differenciá-
ciója figyelhetô meg, mely megvastagodott epidermiszt,
csökkent vagy hiányzó granuláris réteget eredményez.
Emellett fokozottan infiltrálódó T-limfociták, neutrofilek
és leukociták, emelkedett növekedési faktor, citokin és
kemokin kifejezôdés figyelhetô meg pikkelysömörös tü-
netes bôrben a celluláris immunrendszer aberráns aktivá-
ciójának köszönhetôen (2-4). A makroszkópikusan nor-
mális fenotípust mutató, tünetmentes pikkelysömörös
bôr – saját és más kutatócsoportok eredményei szerint –
különbözô eltéréseket hordoz magában az egészségeshez
képest (5, 6).
A kutatások szerint a pikkelysömör patogenezisében
kulcsfontosságú szerepet töltenek be a JAK (Janus kináz)
- STAT (signal transducer and activator of transcription)
jelátviteli útvonalak, amelyek transzkripciós faktorai ab-
normális expressziót és aktivációt mutatnak, ezzel hozzá-
járulnak a pikkelysömör gyulladásos folyamatainak kiala-
kulásához (7, 8).  A különbözô JAK-ok (JAK1, JAK2,
JAK3, Tyk2) eltérô STAT fehérjékkel tudnak kapcsolatba
lépni. A STAT család 7 egymással nagyfokú homológiát
mutató tagból áll (STAT 1, 2, 3, 4, 5a, 5b és 6), specifikus
aktivitást mutatnak, így a funkciójuk széles skálája figyel-
hetô meg a JAK-STAT jelátviteli útvonalakon keresztül
(9, 10). Számos gént képesek aktiválni, míg másokat gá-
tolni, ezáltal hatással vannak olyan alapvetô celluláris fo-
lyamatokra, mint a sejtproliferáció és -differenciáció, a
sejttúlélés, az apoptózis, a migráció és az angiogenezis
(9). Aktivációjuk és deaktivációjuk precízen irányított, né-
hány óra alatt lezajló folyamat (11). 
A STAT1 aktiválódása az interferon (IFN) két külön-
bözô típusa, az IFNα és az IFNγ által valósul meg, ame-
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lyek a JAK1, JAK2 vagy Tyk2
dimerizációját és autofoszfori-
lációját okozzák (10, 12). A
JAK-ok kialakult specifikus kö-
tôhelyeihez kapcsolódó STAT1
molekulák foszforilálódnak,
ezáltal aktiválódnak, és homo-
vagy heterodimer formában a
sejtmagba transzlokálódnak,
ahol növelik számos, az im-
munfolyamatok szabályozásá-
ban részt vevô gén transzkripci-
óját, így több, mint 65 gén exp-
ressziója fokozódik, amely kö-
rülbelül a pikkelysömörben el-
térô szinten expresszálódó gé-
nek 5%-át teszi ki (2, 13, 14). A
STAT1 aktivációjához mind a
Tyr(701), mind a Ser(727) ami-
nosav foszforilációja szükséges.
A Tyr701 foszforiláció elenged-
hetetlen a STAT1 dimerizáció-
jához, míg a Ser(727) a DNS-
kötô affinitásért és a sejtmagba
történô transzlokalizációért, ily
módon az aktivitás kialakulá-
sáért felelôs (15, 16). 
Korábban Hald és munkatársai
leírták az aktivált STAT1 kifeje-
zôdését pikkelysömörös tünetes
bôrben (17). Kutatócsoportunk
megállapította, hogy a STAT1 ak-
tív állapotban van jelen az egész-
séges és a pikkelysömörös tüne-
tes bôrben egyaránt, ellentétben a
tünetmentes bôrrel, ahol jórészt inaktív formában található
(18). Jelen vizsgálatok a pikkelysömörös bôr STAT1 aktivi-
tásának részletesebb vizsgálatát célozták meg.
Anyagok és módszerek
Punch biopsziák
Három középsúlyos-súlyos plakk típusú pikkelysömörös beteget
és három egészséges donort vontunk be a vizsgálatba a 18-60 éves
korosztályból. A 6 mm-es punch biopsziák vétele kezelés nélküli
idôszakban történt, legalább 4 héttel a szisztémás vagy lokális keze-
lést követôen. A PASI (psoriasis area and severity index) értékét
minden betegnél bôrgyógyász határozta meg. A tünetmentes terüle-
tekrôl közvetlenül a lézió mellôl (tünetmentes közeli) és a plakktól
10 cm-re (tünetmentes távoli) vettünk mintákat. A szöveti minták
gyûjtése eleget tett a Helsinki deklarációnak és a Népegészségügyi
Szakigazgatási Szerv szabályainak (2799, 3517). 
Immunhisztokémiai festés
A punch biopsziákat paraffinba ágyaztuk és szobahômérsékleten
tároltuk, majd 5 μm vastagságú metszeteket készítettünk. A metsze-
teket deparaffináltuk és leszálló alkoholsort alkalmazva rehidratál-
tuk a mintákat, ezt követôen pH 6-os citrát pufferrel tártuk fel 95
°C-on 10 percig. A metszeteket 20 percig 0,1% H2O2-ot és 0,6%
NaN3-ot (Sigma-Aldrich) tartalmazó PBS-sel, majd 30 percig kecs-
ke szérumot tartalmazó pufferrel (Invitrogen/ Thermo Fisher Scien-
tific) blokkoltuk. Ezt követôen pSTAT1 Ser(727) és pSTAT1
Tyr(701), (mindkettô 1:400 hígításban, Cell Signaling Technology)
elsôdleges ellenanyagokkal egész éjszakán át 4°C-on inkubáltuk. A
metszeteket PBS-ben mostuk, majd biotinilált kecske anti-nyúl el-
lenanyaggal inkubáltuk szobahômérsékleten 30 percig (1:300,
DAKO An Agilent Technologies Company). Újabb PBS-es mosást
követôen streptavidin/biotin komplexszel (ABC kit, Enzo Life
Sciences Inc.) inkubáltuk 20 percig. Negatív festési kontrollként el-
sôdleges ellenanyag nélküli, csupán PBS-sel inkubált mintát hasz-
náltunk. Az elôhívást 3,3’-diaminobenzidin-nel (DAB) végeztük. A
sejtmag és a citoplazma festése hematoxilin-eozinnal (Sigma-
Aldrich) történt.
Eredmények
A paraffinos mintákon immunhisztokémiai festéssel
vizsgált pSTAT1 Ser(727) forma kifejezôdése mind az
epidermiszben, mind a dermiszben megfigyelhetô (1. áb-
ra). A STAT1 aktivitása korrelál a PASI értékével; magas
PASI esetén (pl. 19,6) a tünetes bôrben intenzívebb
STAT1 kifejezôdés tapasztalható, és ezeknél az eseteknél
a tünetmentes bôr is kismértékû STAT1 aktivitást mutat,
míg alacsony PASI-val bíró betegek (pl. 9,8) esetében ez
nem volt megfigyelhetô. Tünetmentes bôrben a pSTAT1
Ser(727) forma kifejezôdése és a betegek PASI értéke
párhuzamos csökkenést mutat. A pSTAT1 Tyr(701) for-
májának aktivációja nagyon gyorsan lezajlik, ezért csak
magas PASI-jú betegek mintáin figyelhetô meg, ahol
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1. ábra 
Immunhisztokémiai festéssel vizsgálva a pSTAT1 Ser(727) formája nagyfokú
aktivációt mutat tünetes bôrben, egészséges bôrben kisebb mértékben van jelen, 
míg tünetmentes bôrben szinte alig detektálható. A magas PASI-jú betegek
tünetmentes bôre már tartalmaz aktivált STAT1-et, ellentétben az alacsony 
PASI-jú tünetmentes bôrrel (n=3)
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mindkét foszforilációs forma aktivációja jóval intenzí-
vebb (1. táblázat). Összehasonlítotva a tünetmentes lézió-
hoz közeli és attól távoli területekrôl vett punch biopsziák
pSTAT1 formáinak kifejezôdését, megfigyelhetô, hogy a
STAT1 aktivitása független a lézióktól való távolságtól
(n=3) (1. ábra). Az ábrán az is látható, hogy a STAT1
aktiváció legerôsebben a pikkelysömörös tünetes bôrben
mutatható ki. Bár a tünetmentes bôrben a STAT1 jórészt
inaktív, aktivációja magas PASI érték esetén már az
egészséges bôrben tapasztalthoz hasonló mértéket mutat. 
Megbeszélés
Jelenleg a legtöbb kutatás pikkelysömörben a JAK-
STAT jelátviteli útvonal köré csoportosul. A STAT család
tagjai többféle funkciót töltenek be a veleszületett immu-
nitásban. A STAT1 az IFN, az IL-27, az IL-35 és a TLR
közvetített jelátvitelen keresztül aktiválódik (19). Számos
tanulmány beszámol az IFNγ jelátvitel fontosságáról a
pikkelysömör patomechanizmusában (20). A STAT1 szá-
mos gén transzkripciós aktivációját okozza, míg más gé-
nek expresszióját antagonista módon befolyásolja, így
kialakítva egy komplex szignál választ  (21). Pikkelysö-
mörös keratinocitákban a STAT1, az IRF1 (interferon re-
gulated factor 1) és a SOCS1 (az IFNγ szignaling negatív
regulátora) transzkripciós faktorok aberráns regulációja
kontrollálatlan növekedéshez és differenciációhoz vezet-
het (7, 22). 
Kutatócsoportunk korábbi eredményei azt mutatták,
hogy az egészséges egyének bôrébôl származó tenyésztett
fibroblasztokban az aktivált STAT1 szükséges a fibronek-
tin (FN1) és az onkofötális fibronektin (EDA+FN) terme-
lés gátlásához, és a STAT1 gátlása fokozott FN1 és
EDA+FN kifejezôdést eredményez normál humán fibro-
blasztokban. Pikkelysömörös fibroblasztokban ezzel el-
lentétben nem figyelhetô meg az aktivált STAT1 FN1 és
EDA+FN kifejezôdést gátló funkciója (18). Eredmé-
nyeink alapján feltételezhetô, hogy a pikkelysömörös bôr-
ben leírt fokozott FN és EDA+FN kifejezôdés (6, 23) hát-
terében részben a STAT1 abnormális funkciója állhat. Az
aktivált STAT1 kifejezôdése a normál bôrben arra utal,
hogy a szövet homeosztatikus állapotának fenntartásában
a STAT1 aktiváció szerepet játszik. Az a tény, hogy a tü-
netmentes bôrben a STAT1 jórészt inaktivált állapotban
van jelen, szintén a STAT1 aberráns mûködésére utal a
betegségben. 
A JAK-STAT jelátviteli útvonal proinflammatorikus fo-
lyamatainak gátlása kulcsfontosságú lehet az immun-me-
diált bôrbetegségek patogenezisében. Hármas fázisú klini-
kai vizsgálatok folynak kis molekulájú JAK gátlók (tofa-
citinib, ruxolitinib) potenciális terápiaként való hatékony
és biztonságos alkalmazhatóságának megítélésére a pik-
kelysömör kezelésében. Az I. és II. fázis tanulmányok
eredményei dózisfüggô javulást mutattak a pikkelysömö-
rös léziók súlyosságának mértékében a placebo csoport-
hoz viszonyítva.  Számos STAT inhibitorról beszámoltak
az irodalomban (24), azonban STAT1 gátlót még csak ál-
latmodellekben használtak. Wagner és munkatársai hap-
ten-indukálta kontakt hiperszenzitivitást gátoltak STAT1
decoy oligodeoxynukleotidot (dODN) tartalmazó krém-
mel (25). 
Eredményeink arra engednek következtetni, hogy a
STAT1 molekula kulcsfontosságú lehet a pikkelysömörre
való hajlam kialakításában. A pathomechanizmusban be-
töltött szerepének pontos felderítése további vizsgálatokat
kíván.
A munka elvégzéséhez az OTKA K83277, K105985, K111885,
NK105369, PD116992, TÁMOP-4.2.4.A/2-11-1/2012-0001 és A2-
SZGYA-FOK-13-0001 pályázatok nyújtottak segítséget.
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Hazai Hírek
Az MDT Kontakt Dermatitis Munkacsoport 2015. évi ülését a Magyar Dermatológiai Társulat Nagygyûlésén
november 28-án tartotta meg.
Az MDT 88. Tudományos Ülésén önálló szekcióban elhangzott elôadások: a fogászati kontakt allergének
tesztelési lehetôségeirôl (dr. Baló Mátyás), az állati szôrök okozta kontakt szenzibilizációk diagnosztikus nehéz-
ségérôl, klinikumáról (dr. Nagy Gabriella), a hajfestékek okozta igen erôs, hospitalizációs kezelésre szoruló
kontakt szenzibilizációiról (dr. Koller Ágnes Hanna), az MI és a Katon CG szenzibilizáció aktuális adatairól (dr.
Pónyai Györgyi), a higany allergia jelenleg is tapasztalható gyakorlati jelentôségérôl (dr. Fábos Beáta) szóltak.
A kontakt szenzibilizáció tesztelésének értékelési idejére vonatkozó (hazánkban 2007-tôl alkalmazott) meto-
dikai elôírásairól önálló elôadás hangzott el, hivatkozva az ezzel megegyezô 2015 novemberében megjelent eu-
rópai guideline elôírásaira, kiemelve a 7., alkalmanként a 10 napig javasolt tesztreakció követést. Az elôadó
részletezte az epicutan próbák okozta – elenyészônek mondható – mellékhatások lehetôségeit, ezek megelôzé-
sében hangsúlyozta a standard metodika és standard tesztanyagok elônyeit (dr. Temesvári Erzsébet).
A szekció ülést követôen a Munkacsoport az elmúlt év multicentrikus vizsgálatát beszélte meg, melynek so-
rán a hazai epicutan sorba bevezetett methilizotiazolin (MI) tesztelés eredményeit értékelte.
A Munkacsoport felhívta a figyelmet a 2007-tôl alkalmazott hazai tesztelési metodikának megfelelô európai
guideline (Contact Dermatitis 2015. 73,195) epicutan teszt értékelés kritériumára, mely szerint a bôrtesztek ér-
tékelése 20-60 perc, 48 óra, 72 vagy 96 óra és a 7. nap. Hangsúlyozta az egységes tesztelési metodika jelentôsé-
gét a kiadott teszteredmények – alkalmanként szükséges – szakvéleményezésében. 
A Munkacsoport a Magyar Sor antigénjeit – melyek jelenleg európai guidelinenek megfelelnek – nem bôví-
tette.
Budapest, 2015. november 30.
Prof. Dr. Temesvári Erzsébet
egyetemi tanár, a Munkacsoport vezetôje
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